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Abstract
Mutations in the gene coding for the methyl-CpG binding protein 2 (MECP2) cause a severe
form of mental retardation known as Rett syndrome. Almost exclusively girls are affected by
this disease. The first mutations in the X-chromosomal gene MECP2 have been described in
1999, but the molecular mechanisms underlying the disorder are still unknown. MECP2 can
act as a transcriptional repressor and only two neuronal target genes (Bdnf and  Dlx5) have
been identified so far. While MECP2 is expressed ubiquitously, the phenotype of the disease
is  primarily neuronal.  This  suggests  that  MECP2  has  an  important  function  in the  brain,
whereas,  in  peripheral  tissues,  loss  of  function  of  MECP2  might  be  compensated  by
functionally redundant proteins.
To find proteins that  could potentially mediate  such a compensation,  two strategies  were
applied. In a first project, a bioinformatics approach was used to find additional polypeptides
that contain an methyl-CpG binding domain (MBD), the domain of MECP2 which binds to
methylated  CpGs.  Six  new  such  proteins  could  be  detected  and  were  studied  for  their
expression and domain structure. 
A  second  project  aimed  at  identifying  proteins  with  an  overall  amino  acid  similarity  to
MECP2. Such proteins could point to additional, so far unknown functions of MECP2. Two
proteins were identified by database screens and their properties are discussed in this thesis.
The  structure  of  one  of  them,  the  neurofilament  NEFH,  suggests  that  MECP2  has  an
elongated shape. 
To elucidate the target genes of MECP2 in the brain, chromatin immunoprecipitation (ChIP)
was established and combined with a cDNA microarray approach. An animal model for Rett
syndrome was used for this analysis. The microarray experiment showed, that  Mecp2-null
animals  differentially  express  several  genes  that  are  induced  during  stress  response  by
glucocorticoids.  Increased  levels  of  mRNAs  for  plasma  glucocorticoid-inducible  kinase  1
(Sgk) and FK506-binding protein 51 (Fkbp5) were observed. Immunohistochemistry revealed,
that in mouse brains Mecp2 and Fkbp5 as well as Sgk are expressed in the same cells. These
results suggests a modulating function of MECP2 in gene expression regulation rather than a
total repression since the transcriptional repressor MECP2 and its target genes are expressed
in the same cells.. 
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In Fkbp5, three MECP2-binding regions could be determined by ChIP. One of the regions is
also a target site for the glucocorticoid receptor (GR). Therefore a model can be proposed in
which MECP2 and GR compete for a binding site in Fkbp5 and regulate its transcription. In
Rett patients this regulation would be disturbed due to the loss of function of MECP2 leading
to a constant overexpression of glucocorticoid pathway downstream targets and potentially to
several features of the Rett syndrome phenotype.
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1. Introduction
1.1 Rett syndrome
Rett syndrome (RTT) is a genetic neurodevelopmental disorder. It was originally described by
Andreas Rett  in  1966 (Rett,  1966)  and brought  to  attention  of  the  international  scientific
community by Bengt Hagberg and colleagues in 1983 (Hagberg et al., 1983). The disease is
almost exclusively found in females. With an incidence of 1 in 10,000 - 15,000 it is one of the
most common forms of mental retardation in girls.
The peculiar course of the disease with an onset at the age of 6-18 months after an apparently
normal period of growth and development is intriguing and so far unexplained. In a first phase
Rett syndrome clinically presents with regression, loss of speech and loss of purposeful hand
use. Other features include autism, ataxia, stereotypic hand movements such as hand-washing
or -wringing, deceleration of head growth, and epilepsy (Hagberg et al., 1983). After this first
period of regression, patients enter a period of apparent stability that can last for decades. A
final stage is characterized by reduced mobility, i.e. even previously mobile patients lose their
ability  to  walk.  The  life  expectancy  is  around  50  years  (IRSA  homepage
http://www.rettsyndrome.org/main/life-expectancy.htm).
In 1994, Hagberg and Skjeldal defined clinical criteria to classify Rett patients. According to
their categorization scheme, girls of ten years or more have to meet a minimum of three out of
six  primary criteria  and five out  of eleven supportive criteria  to  qualify as classical  RTT
(Hagberg and Skjeldal,  1994).  Patients who do not manifest all the necessary features are
considered to have a variant of the disease, among which the preserved speech variant (PSV)
is the most common one (Zappella 1992, Zappella et al. 1998, De Bona et al. 2000).
Only few male  patients  have  been  described,  and  most  of  them  are  categorized  as  PSV
patients.  In  general,  the  disease  is  considered  as  embryonically  lethal  in  males.  Genetic
mosaicism is believed to be the reason for the survival of some individuals (Clayton-Smith et
al.,  2000;  Renieri  et  et  al.,  2003).  In  addition,  a  boy with  47,XXY  karyotype  has  been
described as well (Schwartzman et al., 1998). 




                                                                                                                                                                                                                                                           
1.2 Mental Retardation
Mental  retardation,  which  is  defined  as  an  intelligence  quotient  (IQ)  <  70,  significant
limitations in two or more adaptive skill areas and an onset before the age of 18, presents a big
medical  and  social  problem (see  Table  1)  (definition  by the  World  Health  Organization,
http://www.who.int) Severe forms of mental retardation with an IQ of 50 or below have a
prevalence of about 0.3 - 0.4% in the population, while mild MR (IQ of 70-50) is as frequent
as 2-3% (Birch et al., 1970, Laxova et al., 1977). 
A  male  excess  of  20%  -  40% has  been  found  in  MR  and  the  different  number  of  sex
chromosomes between males and females  is  regarded as  responsible  for that  observation.
Females can compensate a mutation in a gene on the X-chromosome by the second, wild-type
(wt) allele, whereas in males the mutation will lead to MR.
Developmental
disability














Mental retardation 12.0 ‰ 7061 $ 5249 $ 38927 $ 51237 $ 1014000 $
Cerebral palsy 3.0 ‰ 1175 $ 1054 $ 9241 $ 11470 $ 921000 $
Hearing loss 1.2 ‰ 132 $ 640 $ 1330 $ 2102 $ 417000 $
Vision impairment 1.1 ‰ 159 $ 409 $ 1915 $ 2484 $ 566000 $
a) Present value estimates, in 2003 dollars, of lifetime costs for persons born in 2000, based on a 3% discount rate.
b) Of children aged 5-10 years, on the basis of Metropolitan Atlanta Developmental Disabilities Surveillance Program data
for 1991- 1994.
c) Includes physician visits, prescription medications, hospital inpatient stays, assistive devices, therapy and rehabilitation
(for persons aged < 18 years ), and long-term care (for persons aged 18-76 years), adjusted for age-specific survival.
d) Includes costs of home and vehicle modifications for persons aged < 76 years and costs of special education for persons
aged 3-17 years.
e) Includes productivity losses form increased morbidity (i.e. inability to work or limitation on the amount or type of work
performed) and premature mortality for persons aged < 35 years with mental retardation, aged <25 years with cerebral palsy
and aged < 17 years with hearing loss and vision impairment.
Table  1:  Mental  retardation  is  the  most important  cost  factor  for  the  health  care  system. Estimated
prevalent  and  lifetime  economic  costs  a) for  mental  retardation,  cerebral  palsy,  hearing  loss,  and  vision
impairment, by cost category; United States 2003 (Adopted from Honeycutt et al., 2003)
Many mental  handicaps  have  genetic  causes  and  about  13% of  all  MR cases  have  been
estimated  to  be  caused  by X-chromosomal  gene  defects  (reviewed  by Lubs  et  al.,  1999,
updated by Hamel et al., 2000). X-linked mental retardation (XLMR) has a prevalence of 2.6
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cases per 1000 population (Stevenson and Schwartz, 2002). In spite of recent advances in the
elucidation of the molecular causes of MR (for a review see Ropers and Hamel, 2005) only
for the smaller part of the known forms of MR the relevant genes have been elucidated so far.
But also for the few forms of XLMR, where the underlying genetic cause has been unraveled,
very little is known about the relevant pathogenetic mechanisms. This even holds true for the
most frequent disorder of this group, the fragile X syndrome, where the relevant gene, FMR1,
has been identified in 1991 (Verkerk et al., 1991) and for which scientists only slowly start to
unravel the pathomechanism (Zalfa and Bagni, 2004). 
Studying the pathogenesis of mental retardation is difficult because of the large number of
brain-expressed genes whose functions and interactions are still mostly unknown. In addition,
many of these genes are not expressed in tissues that are readily accessible which greatly
hampers  the  search  for  target  genes or  interacting  proteins.  Postmortem brain  tissue  can
sometimes be obtained from patients  with MR but these tissues usually only reflect the late
stages of the disease.
Animal models therefore can be very helpful to study tissues affected by the disease in detail
at  various  time points.  However,  it  is  sometimes difficult  to  analyze effects  on cognitive
functions in such model organisms.
1.2.1 Mutations in MECP2 cause Rett syndrome
After narrowing the disease locus of RTT to Xq28 by exclusion mapping, a systematic gene
screening approach lead to the identification of mutations in the gene MECP2 (methyl-CpG
binding protein 2) as the cause of RTT (Amir  et al., 1999). Many reports on heterozygous
mutations in this gene associated with RTT have been published since (for a review see Percy
and Lane, 2004). Fewer than 1% of all Rett syndrome cases are familial and therefore, the vast
majority of  MECP2 mutations (99%) are sporadic (Neul and Zoghbi, 2004). Asymptomatic
female carriers have been explained as mosaics or by preferential inactivation of the defective
X chromosome (Amir et al., 1999; Wan et al., 1999).
Three Rett syndrome mouse models have been created so far (Chen et al., 2001, Guy et al.,
2001, Shahbazian et al., 2002). In the first two cases, a part of the gene was eliminated using
the cre/loxP system, thus disrupting MECP2 in its MBD domain (Chen et al., 2001; Guy et
al., 2001) (for details on this protein domain see chapter 1.4). In the third mouse model an N-
terminal truncated form of MECP2 is produced instead of the wt protein. These mice have a
12
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less severe phenotype which resembles the human phenotype more closely in that the mice
show stereotypic forelimb movements (Shahbazian et al., 2002).
Publication Genetic modification Phenotypic features
Chen et al., 2001 CNS-specific  deletion  of  exon  4
by cre/loxP system with a nestin
promoter









death at ~10 weeks
reduced brain size and weight




Guy et al., 2001 Excision  of  exons  3  and  4  by
cre/loxP system




uneven wearing of teeth
misalignment of  jaws
rapid weight loss and death at ~54 days
reduced brain size and weight
males had internal testis
Mecp2+/- females: 
inertia and hindlimb clasping after 3 months 
Shahbazian et al., 2002 Premature stop codon at aa 308
leaves MBD and TRD intact
Mecp2308/y mice (normal until ~6 weeks):
first symptom is a subtle tremor when suspended by tail
tremor worsens with age




fur oily and disheveled
spontaneous myoclonic jerks and seizures
normal brain size and weight
Mecp2+/- females: 
milder and variable phenotype
Collins et al., 2004 Slight  over-expression  of  human
MECP2 from a PAC clone 
normal until ~10-12 weeks







Table 2. The four RTT mouse models. The table summarizes the phenotypic features of the four mouse models
established for  RTT as described in the original publications. This list is  not comprehensive, since only the
features described in the publications were listed and the mice were subjected to different analyses in the studies.
In contrast to the first three mouse models, Mecp2 is overexpressed in the one described by Collins et al.
13
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The phenotypes of the models are summarized in Table 2. 
In  2004,  a  mouse  model,  in  which  the  human  MECP2  was  mildly  overexpresed,  was
described (Collins et al., 2004). Interestingly, these animals presented with forepaw clasping
when hung by the tail, aggressiveness, kyphosis, and hypoactivity characterized by a freezing-
like behaviour. Furthermore, with age they developed seizures and spasticity. Apart from the
aggressiveness these are all features found in RTT.
These models mimic different degrees of severity of the human phenotype with large deletions
of the protein leading to more serious forms of the disease. Luikenhuis and colleagues showed
that a Tau-MECP2 transgene expressed exclusively in neurons could rescue the phenotype of
MECP2 mutant  animals  (Luikenhuis  et  al.,  2004).  This  experiment  substantiates  that  the
phenotypes of these models are indeed due to loss of function of MECP2, particularly in
neurons.  The  mouse  models  therefore  seem  to  be  well  suited  to  study  the  molecular
mechanisms underlying the disease. 
1.3 Gene expression regulation
Before being implicated in RTT, MECP2 had been described as a transcriptional repressor
(Nan  et  al.,  1997).  Transcription  comprises  six  distinct  steps:  (1)  pre-initiation  complex
assembly,  (2)  promoter  opening,  (3)  transcription  initiation,  (4)  promoter  escape,  (5)
transcription elongation, and (6) transcription termination. 
1.3.1 Transcription regulation
Regulation  of  the  above  mentioned  steps  occurs  via  cis-acting  elements  and  trans-acting
factors. Cis-acting elements are DNA sequences in the vicinity of the structural portion of a
gene that are required for proper gene expression (e.g. promoters, enhancers, silencers). Trans-
acting factors are proteins that bind to cis-acting elements to control gene expression.
There  are  three  types  of  trans-acting  factors:  subunits  of  the  RNA  polymerases,  general
transcription factors, and specific transcription factors.
In eukaryotes, subunits of the RNA polymerases bind to the promoter (see Fig. 1 and Fig. 2)
of a gene with the help of general transcription factors (in contrast to prokaryotes, where the
14
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polymerase itself recognizes the promoter).  General transcription factors (also called basal
transcription factors) are required for the initiation of RNA synthesis at all promoters (see
Fig.1). Specific transcription factors on the other hand bind to DNA and interact with other
trans-acting factors. Many transcription factors bind preferentially to a specific DNA motif.
In addition, co-repressors and co-activators can have an influence on transcription in that they
interact with transcription factors (Fig. 1). Co-repressors and co-activators can be: (1) small
molecules that change the properties of a transcription factor, (2) proteins that interact with
transcription  factors  and  have  an  influence  on  the  function  of  the  factor,  or  (3)  protein
complexes  that  associate  with  the  transcription  factor  and  mediate  its  function  (e.g.  co-
repressor complexes that contain histone deacetylases).
Transcription regulation of a gene can be controlled at various levels:
• By direct  influence of  specific  transcription  factors  as  activators  and repressors  on the
assembly of the initiation complex. Activator or repressor proteins directly bind to DNA
(often to specific DNA motifs) or interact with DNA-binding molecules. Their activity is
often modulated by phosphorylation.
• By changes in DNA sequence
• By changes in DNA structure / conformation (ATP-dependent chromatin remodeling)
• By changes in DNA methylation
• By chromatin  protein  alterations  (histone  modification,  histone  exchange,  non-histone
proteins, ATP-dependent chromatin remodeling)
• By non-coding RNA molecules
These  mechanisms  are  not  mutually  exclusive  but  interact  to  form  a  complex  network
regulating transcription temporally and spatially.
In eukaryotes,  mRNA coding genes  are  transcribed by RNA polymerase II (Pol  II).  This
enzyme is recruited to the transcription start site in the promoter of a gene by the TATA-
binding protein (TBP) and the general transcription factor II B (TFIIB). Together with general
transcription  factors  TFIIA,  TFIIE,  TFIIF,  and  TFIIH the  pre-initiation  complex  (PIC)  is
formed and transcription can take place (Fig. 1).
15
1. Introduction
                                                                                                                                                                                                                                                           
Fig. 1. Transcription initiation. This scheme shows the factors build up a pre-initiation complex at the promoter
of a gene. The polymerase is shown in dark blue (Pol II), the general transcription factors (IIA, IIB, IIE, IIF, IIH)
are depicted in blue. The TATA-binding protein and associated factors have a turqouis color. Proximal response
elements (PRE) and distal response elements (DRE) can be bound by transcription factors (in light grey) that can
act as repressors or activators of transcription.
The region around the transcription start site is called promoter and varies from gene to gene.
It can be divided into three subregions: core, proximal and distal promoter. The core promoter
consists of up to 40 bases upstream of the transcription start  site and usually contains the
TATA-box (with a consensus sequence of TAA(A/T)A(A/T)) somewhere between positions -20
and -30 (Fukue et al., 2004). The proximal promoter spans the region up to about -200 bases,
usually  with  a  CAAT-box  which  is  located  at  position  -70  to  -80  with  respect  to  the
transcription start site. Finally, the distal promoter encompasses regulatory sequences up to
2000 bp or  even further  away from the  transcription  start.  This  region  contains  response
elements,  i.e.  DNA  sequences  specifically  recognized  by  transcription  factors  such  as
hormone receptors (see Fig. 1 and Fig. 2).
Other typical sequence features of promoters are DNA stretches of high CpG content (CpG
islands). They are found at about half of all tissue-specific promoters (Suzuki et al., 2001) and
mostly at  promoter regions of RNA polymerase II-transcribed genes (Antequera and Bird,
1993; Macleod  et al., 1998). CpG islands are defined as regions of 500 bp or more with a
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CpG content of at least 55% and a ratio of observed CpGs versus expected CpGs  ≥ 0.65
(Takai and Jones, 2002). CpG islands therefore usually cover the core and proximal promoter
but can extend into the distal promoter as well (Fig. 2). 
In contrast to CpGs elsewhere in the genome, CpG islands are generally hypomethylated. CpG
island methylation is often linked to transcription repression in that hypermethylation of a
promoter-associated CpG island leads to silencing of gene expression (Cedar  et al.,  1983,
Herman et al., 1994, 1996). However, the opposite effect of CpG island methylation has been
observed as well (see section 1.3.3).
Fig.  2.  Representation of  an eukaryotic  promoter.  The relative position of transcription start,  TATA-box
(-20 to -30), CAAT-box (-70 to -80), and the CpG island can be seen. The existence and position of response
elements varies from promoter to promoter.
1.3.2 Epigenetic gene expression regulation
In  eukaryotes,  transcription  regulation  has  an  additional  level  of  complexity  due  to  the
organization of DNA in chromatin. Epigenetics has originally been defined by  Conrad Hal
Waddington in  1942,  and meant  to  describe the process by which genotype gives rise  to
phenotype, i.e. through causal interactions among genes (gene networks) and their products
(Waddington,  1942).  Waddington originally defined epigenetics as “the branch of biology
which  studies  the  causal  interactions  between  genes  and  their  products  which  bring  the
phenotype into being” (Waddington, 1942).
Due to the increasing complexity of the field and the elucidation of underlying mechanisms,
that were not known to Waddington, the definition of epigenetics has changed over time. The
discovery of DNA and its organization as chromatin has lead to new insights in the correlation
of genotype and phenotype and hence to a new definition of epigenetics as  “the study of
mitotically and/or meiotically heritable changes in gene function that cannot be explained by
changes in DNA sequence” (Russo et al., 1996).
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Recently, another modification of the definition of epigenetics has been proposed, motivated
by the fact that the mechanisms underlying changes in the chromatin state are also relevant for
cells that are not dividing anymore (e.g. differentiating stem cells):
Epigenetics  is  the  study  of  changes  in  gene  transcription  that  cannot  be  explained  by
changes in DNA sequence (Roloff and Nuber, 2005).
Mechanisms underlying epigenetic gene expression regulation are summarized in Fig. 3.
Fig.  3. Summary of epigenetic mechanisms.  The
basic components of epigenetic gene regulation are
depicted in orange, possible modifications to DNA
or proteins are shown in yellow, and enzyme classes
mediating  the  modifications  are  colored  in  blue.
(Adopted form Roloff and Nuber, 2005)
1.3.3 DNA methylation
One major mechanism of epigenetic gene expression regulation is the methylation of DNA. In
mammals,  this  primarily occurs  at  the  5’  position  of  the  cytidine  ring structure  of  CpGs
(Fig. 4). Ramsahoye and colleagues (2000), showed that cytosines followed by a base other
than G (especially CpA) can also be methylated, albeit to a lesser extent.
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Fig. 4. Cytosines can get methylated at the 5' position .
The  DNA  methylation  of  many  gene  regulatory  regions  inversely  correlates  with  gene
expression. Here, DNA methylation does not seem to be essential for the initiation but rather
for  the maintenance of  gene silencing (Bird,  2002).  Although true for  many genes,  DNA
methylation is not generally linked to gene silencing. For example, the unmethylated H19
imprinting control region leads to repression of the maternal IGF2 allele and its methylation
leads to the expression of the paternal IGF2 allele (Holmgren et al., 2001).
DNA methylation is established and maintained by DNA methyltransferases (DNMT) while
demethylation  takes  place  by  passive  mechanisms  (i.e.  absence  of  maintenance  DNMT
activity) or enzymatic activity. Different reports on active demethylation in mammals have
been published.  DNA glycosylase activities  were described  (Zhu et  al.,  2000,  Vairapandi
2004) and a direct removal of the methyl group from the cytosine has been proposed but also
disputed (Ramchandani et al., 1999, Wade et al., 1999); finally, proteins of the Aid/Apobec1
family can convert  cytosine to  uracil  by deamination,  thus  leading to excision  repair  and
replacement of the uracil by an unmethylated cytosine (Morgan et al., 2004).
DNA  methylation  is  carried  out  by  the  DNA  methyl  transferase  protein  family  that,  in
mammals, can be split into three distinct classes: DNMT1, DNMT2 and DNMT3. DNMT3a
and DNMT3b have originally been described as  de novo methyltransferases (Okano  et al.,
1998, Okano  et al., 1999) while DNMT1 maintains methylation. However, recent findings
suggest a direct interaction between DNMT1 and DNMT3a/3b (Hattori  et al., 2004, Kim et
al.,  2002;  Rhee  et  al.,  2002)  and hence involvement  of  all  proteins  in  both mechanisms.
DNMT2  was  found  as  a  homologue  to  the  Schizosaccharomyces  pombe DNA
methyltransferase (Okano et al., 1998) and weak methyltransferase activity of this protein has
been shown in Drosophila, mouse, and man (Tang et al., 2003, Hermann et al., 2003). 
Finally, the number of methylated cytosines in CpA and CpT motifs has been shown to be
decreased in differentiated tissue as compared to ES cells  (Ramsahoye  et al.,  2000). This
raises the question whether these methylated motifs, in addition to CpG methylation, play a
role  in  gene  expression  and  chromatin  state  regulation and  what  proteins  mediate  these
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methylation signals.
DNA  methylation  is  associated  with  many  genetic  diseases,  for  example:  Prader-Willi
syndrome (Prader  et  al.,  1956), Angelman  syndrome  (Kishino  et  al.,  1997),  and  ICF
(Immunodeficiency - Centromeric instability - Facial anomalies) (Xu et al., 1999). In addition,
developmental  abnormalities  and  certain  tumors  can  originate  from  abnormal  DNA
methylation  (Yoder  et  al.,  1996).  Rett  syndrome (Amir  et  al.,  1999)  is  a  genetic  disease
indirectly associated with DNA methylation since the product of the disease causing gene
binds to m5CpG.
There is a global and a local aspect of transcription regulation by DNA methylation. While
changes in activity of DNMTs can have an effect on gene expression in the whole genome,
single genes have to be regulated specifically by methylation of CpGs at prominent positions
(e.g. in the promoter or in other regulatory sequences of these genes). How the site-specific
regulation works in detail is poorly understood.
DNA methylation at CpGs has been shown to often correlate with histone deacetylation. This
link can be explained by the interaction of methyl-CpG binding proteins (see chapter 1.4.)
with complexes containing histone deacetylases (HDAC) (Nan et al., 1998, Ng et al., 2000;
Zhang et al., 1999).
1.4 MBD proteins
The effect of DNA methylation is mediated by proteins that recognize m5CpGs, namely the
members  of  the  methyl-CpG  binding  domain  (MBD)  protein  family  and  Kaiso
(Prokhortchouk et al., 2001; Hendrich and Tweedie, 2003; Roloff et al., 2003). These proteins
recognize m5CpGs and can interact with different co-repressor complexes and hence act as
translators of DNA methylation patterns for transcription regulation. 
MBD proteins contain a methyl-CpG binding domain which consists of ~70 residues in an
α/β-sandwich fold built  of three to four  β-twisted sheets and a helix  with a characteristic
hairpin loop in the opposite layer (Ohki et al., 1999, Wakefield et al., 1999) (see Fig. 5). The
prototype  of  this  domain  has  been  shown  to  allow  specific  binding  to  symmetrically
methylated CpGs (Nan et al., 1993).
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Fig. 5. Structure of the MBD domain of human MECP2. The MBD domain consists of three β-twisted sheets
(indicated by arrows) and one main α-helix (indicated by H1 and H2) (protein chain from PDB protein data
bank). On the right, the 3D structure of a methyl-CpG binding domain interacting with DNA is shown. The two
methyl groups are depicted in black, the DNA is represented on the right, the MBD is on the left. (Adopted from
PDB)
Members of this protein family are found in vertebrates as well as invertebrate animals. At the
beginning of this thesis in 2001, five vertebrate MBD proteins were known: MBD1, MBD2,
MBD3, MBD4, and MECP2 (for a review see: Ballestar and Wolffe,  2001, Hendrich and
Tweedy,  2003).  Except  for  MBD4,  all  of  them  are  associated  with  histone  deacetylases
(HDAC), and a transcriptional repression mechanism mediated by the recruitment of HDACs
has  been  shown  for  MECP2,  MBD1,  and  MBD2  (Nan  et  al.,  1993,  Ng  et  al.,  2000,
Prokhortchouk et al., 2001).  
1.4.1 MBD1
MBD1 binds symmetrically methylated CpGs, preferably if they are separated by few bases
(Ballestar and Wolffe, 2001). Five isoforms of MBD1 are generated by alternative splicing,
resulting  in  proteins  that  contain  one  MBD  domain,  two  to  three  cysteine-rich  (CXXC)
domains,  and  different  C-termini  (Expasy database:  MBD1_human).  All  isoforms repress
transcription from methylated promoters  in vitro (Fujita  et al., 1999). In addition, isoforms
with three CXXC domains also repress unmethylated promoter activity (Fujita  et al., 1999).
Suv39h1, a histone methyltransferase, enhances MBD1-mediated transcriptional repression by
binding the MBD, not  the C-terminal  transcriptional repression domain of MBD1. MBD1
indirectly  binds  to  histone  deacetylases  through  Suv39h1,  causing  methylation  and
deacetylation of histones that are associated with gene inactivation (Fujita N  et al., 2003a).
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Recent data show that MBD1 forms a stable complex with histone H3-K9 methylase SETDB1
and binds to CHAF1B (p60 subunit  chromatin assembly factor I (CAF-I) required for the
assembly of histone octamers onto newly-replicated DNA) (Sarraf and Stancheva, 2004). A
molecular link between p59 OASL and MBD1 has been established in the context  of an
interferon-stimulated cell (Andersen et al., 2004). p59 OASL is a protein that binds to RNase
L leading to repression of gene expression by general RNA degradation.
Besides its repressive function, MBD1 interacts with the transcription activator MCAF via the
transcriptional repression domain of MBD1 (Fujita N et al., 2003b).
Apart from gene expression regulation, MBD1 also regulates cell cycle G1-S transition and
apoptosis via the p53/p21 (Waf1) pathway (Kano et al., 2004).
In  addition,  MBD1 interacts  with  MPG (a  methylpurine-DNA glycosylase  which  excises
damaged bases from substrate DNA) via its  transcription repression domain (TRD). Upon
DNA damage by methylmethanesulfonate or a similar alkylating agent,  MBD1 binding to
DNA is  lost,  MPG binds  to  the  damaged sites,  blocks  gene  expression  and reverses  the
damage (Watanabe et al., 2003).
A knockout mouse model for Mbd1  (Mbd1-/-) shows more or less normal development but
increased  genome instability,  decreased  adult  neurogenesis,  and  impaired  spatial  learning
(Zhao et al., 2003).
1.4.2 MBD2
The MBD2 protein contains an MBD domain and a coiled coil region. It binds to m5CpGs in
highly  methylated  regions  (Ballestar  and  Wolffe,  2001),  but  in  complex  with  MBD3,  a
binding to hemi-methylated DNA is also possible (Tatematsu et al., 2000).
There are three transcript variants: MBD2a is the full transcript, MBD2b is lacking the first
149 aa and the third variant has a different C-terminus (Expasy database: MBD2_human).
MBD2 has been shown to recruit the co-repressor complex Mi-2/NuRD to methylated DNA
in  vitro (Zhang  et  al.,  1999),  thereby  mediating  chromatin  condensation  via  histone
deacetylation and gene expression repression. Interestingly, the Mi-2/NuRD complex contains
MBD3 (see chapter 1.4.3). Two ubiquitously expressed and highly related p66 proteins seem
to  be  part  of  this  repression  complex.  In  addition,  both  interact  with  MBD2,  albeit  with
different binding domains (Brackertz et al., 2002). MBD2 also binds to the Sin3A repressor
via the MBD domain (Boeke et al., 2000).
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Bakker and colleagues showed that MBD2 represses transcription from hypermethylated pi-
class glutathione S-transferase gene promoters in hepatocellular carcinoma cells (Bakker  et
al., 2002). 
In contrast  to the examples of unspecific repression shown above, sequence specificity of
MBD2 mediated repression can be achieved by the interaction with MIZF. This zinc finger
protein binds to CGGACGTT motifs if methylated and, by interplay with MBD2, leads to
repression of the genes in that region (Sekimata and Homma, 2004). Furthermore, MBD2 has
a role in the methylation-mediated inhibition of ribosomal RNA gene expression (Ghoshal et
al., 2004). MBDin – a GTPase shown to bind to MBD2a at the extreme C-terminus - relieves
MBD2 repression  and reactivates  transcription  from methylated promoters  (Lembo  et  al.,
2003).
On the other hand, MBD2a and RNA helicase A cooperatively enhance CREB-dependent
gene expression (Fujita H et al., 2003), thus activating instead of repressing gene expression
at a methylated promoter element.
The MBD2 protein has also been proposed to act as a DNA demethylase in vitro and in vivo
(Bhattacharya et al., 1999; Cervoni and Szyf 2001, Detich et al., 2002) leading to activation of
CpG sites within the promoter region of reporter genes. This however has been questioned
(Ng et al., 1999, Wade et al., 1999, Boeke et al., 2000).
MBD2 is also interesting in the context of cancer. A study by Patra et al. shows that MBD1 is
expressed in different prostate cancer tumor cell lines, but MBD2 and MECP2 are not (Patra
et al., 2003).
MBD2 gene expression may be a significant factor in tumorigenesis, in that high levels of
MBD2 expression correlate with reduced risk of cancer (Zhu et al., 2004). This is in contrast
to the observation, that antisense oligoDNA for MBD2 suppresses tumor growth in nude mice
(Campbell et al., 2004).
MBD2  not  only  suppresses  transcription  of  Pol  II-transcribed  genes  but  also  of  Pol  I-
transcribed rRNA genes. 
A  knockout  mouse  model  for  Mbd2 (Mbd2-/-)  has  been  created  by  Bird  and  colleagues
(Hendrich et al., 2001). These mice are viable and fertile but the nurturing behavior of Mbd2-/-
mothers is disturbed. Furthermore, the Mbd2-/- mice show normal DNA methylation patterns,




                                                                                                                                                                                                                                                           
Mbd2-/-/Mecp-/y double  knockout  mice  showed  the  same  phenotype  as  Mecp2-/y mice
suggesting  no  direct  genetic  interaction  between  Mecp2  and  Mbd2 (Guy  et  al.,  2001).
Reduced  survival  of  mice  with  mutations  of  Mbd3 in  an  Mbd2-/- background,  however,
suggested a genetic interaction between these two proteins (Hendrich et al., 2001).
1.4.3 MBD3
MBD3 only interacts non-specifically with DNA (Fraga  et al.,  2003) and unlike the other
family members, MBD3 is not capable of binding methylated DNA. However, it is involved
in repression of transcription as a component of a co-repressor complex (Zhang et al., 1999).
MBD3 (Expasy database:  MBD3_human)  is  a  subunit  of  NuRD,  a  multisubunit  complex
containing nucleosome remodeling and histone  deacetylase activities.  MBD3 mediates the
association  of  metastasis-associated  protein  2  (MTA2)  with  the  core  histone  deacetylase
complex.
Mbd3 knockout mice (Mbd3-/-) die during early embryogenesis (Hendrich et al., 2001).
The Drosophila melanogaster homolog of MBD3 has been shown to mediate the interaction
between the MI-2 chromatin complex and CpT/A-methylated DNA (Marhold et al., 2004).
Two proteins homologous to MBD3 have been found. MBD3L1 and MBD3L2 have no MBD
domain and do not bind to m5CpGs in vitro (Jiang et al., 2002). MBD3L1 is a trancriptional
repressor that interacts with MBD2 and the NuRD complex. Mbd3l1 knockout mice are viable
and fertile suggesting that the protein is not essential and its function probably redundant to
MBD3 (Jiang et al., 2004).
1.4.4 MBD4
In contrast  to  the  other  MBD family members,  MBD4 (Expasy database:  MBD4_human)
preferably binds to  m5CpG/GpT mismatches instead of symmetrically methylated m5CpGs.
Such mismatches can result from spontaneous deamination of methylated cytosines. MBD4
can reverse the mismatch by excision of the thymine (Hendrich et al., 1999, Petronzelli et al.,
2000).  Furthermore,  MBD4 gene  mutations  are  detected  in  tumors  with  primary
microsatellite-instability (MSI), a form of genomic instability associated with defective DNA
mismatch repair, and the MBD4 gene meets 4 of 5 criteria for a bona fide MSI target gene.
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1.5 MECP  2  
MECP2 is the founder of the MBD protein family, in that it was the first family member to be
cloned (Lewis et al., 1992).
1.5.1 Human MECP2: Gene structure and mutations  
The MECP2 gene maps to Xq28 spanning 76kb and is composed of four exons transcribed
from telomere to centromere. Its transcript of 1461 nucleotides was originally described with a
coding sequence in exons 2-4. A second isoform has been isolated in 2004 with a transcript
encompassing exons 1, 3,  and 4 (Kriaucionis  and Bird,  2004, Mnatzakanian  et  al.,  2004)
(Fig. 7). Since exon 2 consists of only 124 nucleotides, the size of the coding sequence is
almost the same, explaining why the second isoform was not detected earlier.
The original isoform is now called MECP2e2, while the new isoform lacking exon2 is called
MECP2e1  (where  e1  and  e2  stand  for  exon1  and  exon2).  Until  2004,  the  presence  of
MECP2e1 was not known and previous studies did not take that difference into account. In
general, only MECP2e2 was studied, or both isoforms were analyzed without being aware of
that fact. If not further specified, the use of the abbreviation MECP2 therefore indicates that
the study did not distinguish between MECP2e1 and MECP2e2.
Fig. 6. Distribution and frequency of mutations in  MECP2e2.  The height of the lines indicates how many
individuals carrying a mutation at this site have been found. Mutation hot spots are seen in the MBD and the
TRD domain. (adopted from RettBASE).
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Following the  elucidation  of  MECP2 as  disease gene  for  RTT,  variations  in  its  genomic
sequence have been  studied  intensively.  RettBASE,  a  MECP2  variation  database features
more than 290 amino acid exchanges, insertions, and deletions in a total of 1595 cases from
61 publications and from many direct entries (Fig. 6). 
Early nonsense mutations (leading to a stop codon in the 5' part of the gene) likely lead to loss
of  the  transcript  via  nonsense-mediated  mRNA  decay,  whereas  late  nonsense  mutations
(leading  to  a  stop  codon  in  the  3'  part  of  the  gene)  likely result  in  a  truncated  protein.
Nonsense mutations within the methyl-CpG-binding domain have been experimentally shown
to abrogate methylation-specific  binding to  DNA (Yusufzai  and Wolffe,  2000).  However,
most of the truncating mutations to be found in RettBASE are distal to the MBD, and one
hypothesis holds that the truncated proteins still  bind methylated DNA but cannot interact
with  co-repressor  complexes.  Experimentally,  nonsense  mutations  within  the  TRD  were
shown to result  in premature truncations and the resulting proteins were unable to repress
transcription (Yusufzai and Wolffe, 2000).
Investigations by Yusufzai and Wolffe (2000) revealed that missense mutations within the
MDB abrogated methylation-specific binding to DNA. Different functional consequences of
MECP2 mutations are conceivable: 
A  complete  functional  loss  of  the  protein  as  a  transcriptional  silencer  might  lead  to
transcriptional upregulation of target genes, as for instance suggested by studies on the MDR1
gene (El-Osta and Wolffe, 2001, El-Osta et al., 2002), the imprinted genes H19 (Drewell  et
al., 2002), and U2afl-rsl (Gregory et al., 2001). Altered replication timing of the inactive X
chromosome  in  a  portion  of  lymphocytes  from  RTT  patients  as  well  as  a  decreased
compaction of heterochromatic regions on chromosome 9 have been reported together with
the idea of a connection between RTT and X-chromosome replication disturbance (Vorsanova
et al., 1996; Vorsanova  et al., 1998). Moreover, indirect effects of mutations might occur.
Loss of DNA binding capability could lead to an interaction with unmethylated sequences in a
non-specific manner with a persistent binding to co-repressors or to no interaction with DNA
at all.
As reported by Amir  et al. (2000), the influence of the mutation type on the phenotype (13
clinical  traits)  was  analyzed  in  48  RTT  patients.  Correlations  were  only  found  between
truncating  mutations  and  two  parameters  (breathing  abnormalities  and  low  levels  of
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homovanillic acid in cerebrospinal fluid). Neither the overall severity score nor any of the
other parameters correlated with the type of mutation. Cheadle et al. (2000) reported missense
mutations to have significantly milder clinical consequences than truncating mutations, but
these  findings  are  not  confirmed  by the  study of  Huppke  et  al. (2000).  In  both  studies,
however,  several  patients  with  identical  mutations  but  widely  different  phenotypes  are
described, thereby illustrating that the significant clinical variability seen in RTT cannot be
ascribed to allelic differences alone.  
Mutations in  MECP2 have been found in patients with widely varying phenotypes. In two
reports dealing with familial MECP2 mutations, male patients were described which present
with severe non-specific X-linked mental retardation, but display few if any signs of RTT
(Meloni et al., 2000; Orrico et al., 2000). Female patients with random X-inactivation pattern
did not present with RTT syndrome, but with a mild form of mental retardation (Meloni et al.,
2000; Orrico et al., 2000). Thus, the phenotypic variability of MECP2 mutations can in part
be explained by skewed X-inactivation and by different types and positions of mutations. In
addition, a digenic model has been proposed in which RTT is considered as a disease that
develops when a de novo mutation in MECP2 occurs in the presence of a mutation in another
gene. According to this model, MECP2 mutations alone would produce a recessive phenotype
of non-specific mental retardation, whereas a mutation in the second gene alone may produce
no phenotypic effect at all (Meloni et al., 2000). On the other hand, MECP2 mutations have
been found in up to 80% of sporadic and approximately 50% of familial cases, which clearly
opposes the digenic model.
The 20% of missing mutations may be due to the fact that large non-coding regions of the
gene  as  well  as  the  promoter  have  generally  not  been  screened  for  mutations, that  the
existence of microdeletions as well as large rearrangements have often been neglected, and
that there might be mutations in the coding region of MECP2e1. One patient has been shown
to have a mutation in the coding region of MECP2e1 (Mnatzakanian et al., 2004). However,
another  study could  not  find  any mutations  in  the  promoter  or  exon  1  of  MECP2 in  97
mutation-negative RTT patients (Evans et al., 2004)
1.5.2 MECP2: Protein structure
Besides the MBD, MECP2 also contains two AT-hooks,  a TRD, two nuclear localisation
sequences (NLS), a N-terminal segment with a group II WW domain binding region (WWBR)
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and a C-terminal part with a histidine- and a proline-rich region. The location of the domains
relative to the transcripts and the genomic arrangement can be seen in Fig.7.
Fig. 7.  MECP2 genomic, transcript, and protein structure.  Human MECP2: genomic organization (in the
middle),  mRNAs and  domain  organization  of  MECP2e1  (top)  and  MECP2e2  (bottom)  proteins.  The  three
different transcripts for each splice variant are denoted by the different poly-A tail sizes that are possible.
AT-hooks are DNA binding motifs of eleven residues that  allow binding to the minor grove
of preferably A/T rich regions.
TRD  describes  a  protein  domain  that  can  mediate  transcription  repression,  usually  via
interaction with histone deacetylase containing protein complexes. The TRD of MECP2 can
bind to TFIIB in vitro (Kaludov and Wolffe, 2000). Repression by MECP2 as well as by a
TRD fusion product correlates with selective assembly of large nucleoprotein complexes. This
suggests, that even in the presence of initiation factor components, a repressor complex can be
established, preventing transcription initiation.
There are two nuclear localization signals,  one  lying between nucleotides 173 and 193 of
MECP2e2 and one located within the TRD region.
The C-terminal segment was shown to facilitate the binding to the nucleosome core (Chandler
et  al.,  1999).  WW  domains,  present  in  the  C-terminal  portion,  are  characterized  by two
tryptophane  (W)  residues  and  bind  to  prolin-rich  regions.  According  to  the  recognition
sequence these domains are classified into four groups. Group II domains specifically bind
PPLP  (pro-pro-lys-pro)  motifs.  The  domain  is  found  at  aa  residues  384-387  in  human
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MECP2e2.
Histidine and proline-rich stretches as found in the C-terminal region are conserved in certain
neural-specific transcription factors (Vacca et al., 2001).
The human and mouse 3'UTR contain eight regions of closely conserved sequence similarity
which has led to the suggestion that they may be involved in stabilization of the transcript as
well as in post-transcriptional regulation (Coy et al., 1999).
MECP2e1 furthermore features a polyalanine (poly-A) and polyglycine (poly-G) tract in its 21
aa specific N-terminal sequence. Poly-A and poly-G stretches are also found in members of
the homeobox family (Mnatzakanian et al., 2004; Utsch et al., 2002)
1.5.3 MECP2: Function
MECP2 can function as a transcriptional repressor. The MBD of MECP2 is necessary and
sufficient for DNA binding  in vitro and allows MECP2 to preferentially recognize a single
symmetrically  methylated CpG in diverse sequence contexts (Nan  et al., 1993). MECP2 is
abundantly  found  in  the  heavily  methylated  pericentromeric  heterochromatin  of  mouse
chromosomes  (Lewis  et  al.,  1992)  and  a  transiently  expressed  MECP2  fusion  protein  is
targeted to methylated heterochromatin (Nan et al., 1996). Furthermore it was found to bind to
nuclear matrix attachment regions, the putative anchorage sites of chromatin loop domains
(von Kries et al., 1991).
Transcriptional repression has been described to be mediated by MECP2 in five different
reports.  The mechanism described in the first  two reports  rely, to a significant  extent,  on
histone deacetylation.
1. A histone deacetylation-dependent mechanism of transcriptional repression is realized by
the interaction of the TRD with the co-repressor mSin3A which in turn is part of a large co-
repressor complex containing histone deacetylases HDAC1 and 2 (Nan  et  al.,  1998).  The
deacetylation of histones allows DNA to wind more tightly around the histone, preventing
access of the transcription machinery to the promoters. 
This mechanism has been questioned in 2004 by Klose and Bird. They showed that MECP2
exists as an elongated monomer and that its interaction with Sin3A is not stable. This also
correlates with the observation that ARBP (the chicken MECP2) has an elongated shape (von
Kries et al., 1994).
2. In 2001 Kokura and colleagues showed that MECP2 interacts with Ski and N-CoR (Kokura
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et al., 2001), a complex containg HDACs (for a review see Jones and Shi, 2003).
3. A histone deacetylase-independent mechanism of repression was demonstrated by transient
transfection studies using a reporter plasmid containing the SV40enhancer/promoter (Yu  et
al., 2000). In this setting, TRD–mediated transcriptional repression could not be relieved by
the specific histone deacetylase inhibitor TSA. However, TRD-mediated repression using a
different promoter (adenovirus major late promoter) could be relieved by TSA, indicating that
the mode of action, histone deacetylase-dependent or –independent, relies on the promoter
context. 
4. Another way of transcription repression mediated by MECP2 is the blocking of binding
sites  for  transcription  factors.  This  has  been shown for the E2F binding site  at  the Rb-1
promoter in tumor cells (di Fiore et al., 1999). Also, MECP2 has been demonstrated to inhibit
the assembly of the basal transcriptional machinery at methylated promoters in the absence of
chromatin assembly and to associate with TFIIB in vitro (Kaludov and Wolffe, 2000). 
5.  MECP2 links  DNA methylation  and histone  methylation  by interaction with  a histone
methylase whose nature is yet unknown. This interaction reinforces the repressive function of
DNA methylation by recruitment of proteins that can methylate histones (Fuks et al., 2003a,
Fuks et al., 2003b).
Gene repression by MECP2 can be a dynamic process. For example, membrane depolarization
of primary neurons leads to a dissociation of MECP2 from a  Bdnf promoter and increased
Bdnf expression. This change is accompanied by chromatin changes at this site (Chen et al.,
2003; Martinowich et al., 2003).
MECP2 also seems to be involved in maintenance of DNA methylation. MECP2 binds to
hemimethylated  CpGs  after  DNA  replication  and  can  recruit  DNMT1  which  then  fully
methylates the CpG (Kimura and Shiota, 2003).
MECP2 therefore has a double function in repressing gene expression as well as maintaining
the methylation pattern for continuous repression.
1.5.4 MECP2: Expression
The MECP2 gene is ubiquitously expressed. Although early developmental stages show low
levels  of  expression,  MECP2 is  widely active  in  embryonic  and  adult  tissues.  In human
tissues,  originally three  different  transcripts  (1.8  kb,  ~7.5  kb,  and  10  kb),  resulting  from
differential use of polyadenylation signals, have been described in most tissues with tissue-
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specific variation in expression: brain and spinal cord show higher expression of the long
transcript (10 kb) whereas the smaller transcript (1.8 kb) is more abundant in other tissues,
e.g. muscle and lymphoid tissues (D'Esposito et al., 1996; Reichwald et al., 2000). These two
transcripts  have  similarly short  half-lives,  and the  functional  significance,  if  any, of  their
differential expression is unkown.
Due to the splice variants, a total of 6 transcripts could exist, at least in principle (2 variants
with 3 different polyadenylation signals each)(Fig. 7). The MECP2e1 variant has been shown
to be ubiquitously expressed as well. In adult human brain,  MECP2e1 levels were 10 times
higher than MECPe2 while in other tissues MECP2e2 transcripts are expressed more strongly
(Mnatzakanian et al., 2004).
1.6 Techniques
1.6.1 DNA microarrays
Gene  expression  profiling  on  a  large  scale  is  nowadays  mostly  performed  using  DNA
microarrays (for a review on DNA microarray techniques see Stoughton, 2005). 
Basically three types of DNA microarrays can be distinguished depending on the material
immobilized on the array: cDNA, oligonucleotide, and genomic arrays. For this study, cDNA
microarrays were used.
In such expression studies, the RNA of interest (i.e. from cell type or tissue after a certain
treatment or at a certain cellular state) is labeled during reverse transcription into cDNA. The
labeling  is  achieved  by  incorporating  fluorescent  dyes  during  the  reverse  transcription
procedure. To compare two samples, the cDNAs are labeled with different dyes and then co-
hybridized to a microarray containing large numbers of PCR-amplified cDNAs. Every PCR-
amplified cDNA sample on the array has been spotted to a different area. After hybridization
of the labeled cDNAs, a laser scanner allows to detect specific fluorescent signals for every
spot on the array. The comparison of the two signals of the co-hybridized cDNA pools shows
the relative presence of each cDNA sequence that corresponds to RNA levels in the target
sample. The more cDNAs are spotted on the array, the more mRNA levels can be studied. For




                                                                                                                                                                                                                                                           
1.6.2 Chromatin immunoprecipitation
To study in vivo  DNA-protein interactions, chromatin immunoprecipitation has become the
method of choice (for a review see Das et al., 2004). Basically, DNA and interacting proteins
are cross-linked in cells, the chromatin is then cleaved into small pieces (e.g. by shearing) and
the  DNA fragments  of  interest  (i.e.  bound  by the  protein  to  be  studied)  are  isolated  by
immunoprecipitation with a specific antibody. After reversal of the cross-linking,  obtained
DNA fragments can be analyzed in several ways such as sequence-specific PCR, sequencing,
or hybridization to a genomic DNA microarray (Fig. 8).
Fig.  8.  Scheme  of  chromatin  immunoprecipitation.
Protein-DNA complexes are linked (red dots) in cells by the
use  of  formaldehyde.  The  chromatin  is  then  sheared  into
small  fragments  and  the  protein  of  interest  (blue)  is
immunoprecipitated with a specific antibody bound to protein
A-agarose (black). After washing steps and unlinking, DNA
fragments that were bound to the protein of interest can be
isolated. To characterize these fragments basically 3 methods
exist.  The  fragments  can  be  labeled  and  hybridized  to  a
genomic DNA microarray. They can also be cloned into a
vector  and  sequenced.  Finally,  they can  be  amplified  with
primers  specific  for  a  genomic region.  The  last  method is
especially useful if potential target sites are known (e.g. from
prior gene expression studies).
Many steps in this approach have to be optimized depending on the biological material used,
the protein studied, and the method for the analysis of the DNA fragments obtained by ChIP.
ChIP is especially suited for transcription factors with many genomic binding sites, such as
MECP2, since it possibly supplies all target sequences in only one experiment. 
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1.7 Open questions and approaches
Even  though  a  lot  of  facts  have  been  gathered  about  RTT  and  MECP2,  the  molecular
mechanisms underlying this disease remain unknown. To understand the pathomechanism of
RTT, the transcriptional consequences of MECP2 mutations and target genes of this protein
need  to  be  identified.  Gene  expression  profiling  with  DNA microarrays  has  become  the
method of choice for studying the expression of large numbers of transcripts in parallel. This
technique  is  especially  suited  if  the  disease  gene  is  a  transcriptional  regulator,  such  as
MECP2.  To  confirm  the  binding  of  MECP2  to  the  potential  target  genes,  ChIP  was
performed.
Since the beginning of  this thesis, in three published studies related to RTT, the microarray
technology has  been  applied.  Post  mortem RTT brains,  brain  tissue  from a  RTT mouse
models and lymphoblastoid cell lines were used  respectively (Colantuoni et al., 2001, Tudor
et al., 2002, Ballestar et al., 2005). None of the studies has however revealed genes regulated
by MECP2 that would plausibly explain the RTT phenotype. A distinct feature of RTT is, that
apart from the brain, mutations in MECP2 do not seem to have a strong effect on other organs.
This could be explained by compensation of loss of function of MECP2 by proteins with
similar properties. Finding such proteins could help to understand the exact role of MECP2
and why the loss of MECP2 function primarily shows an effect in the brain.
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1.8 Goals of the thesis
This thesis therefore had two goals:
1. The first goal was to find proteins that could compensate for the loss of function of
MECP2 in peripheral tissues.
To  do  so,  2  projects  were  designed.  "The  detection  of  MBD  protein  family
members formerly not recognized" to find proteins with an methyl-CpG binding
domain that might, like MECP2, act as transcriptional repressors, and "the search
for  paralogues of MECP2", that might be structurally and functionally related to
MECP2.
2. The  second  goal  was  to  identify  "MECP2  target  genes"  in  the  brain,  and  to
determine pathways involved in the pathogenesis of RTT.
These studies should give new insights  into the pathogenesis  of RTT and should help to
explain  why loss  of  function  of  the  ubiquitously expressed  gene  MECP2 gives  rise  to  a
syndrome that is primarily confined to the nervous system.
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2. Materials and Methods
2.1 Materials
2.1.1 Chemicals
Standard chemicals  were ordered from Amersham (Amersham Pharmacia Biotech Europe
GmbH, Freiburg, Germany), Biochrom (Berlin, Germany), Calbiotech (Bad Soden, Germany),
Invitrogen (Karlsruhe, Germany), Merck (Darmstadt, Germany), Roche Biochemicals (Basel,
Switzerland), Roth (Karlsruhe, Germany), Sigma-Aldrich (Sigma-Aldrich Chemie, Munich,
Germany)  in  the  quality  pro  Analysis  (p.a.).  For  special  chemicals  and  solutions,  the
manufacturer's name is indicated in the individual methods section.
Buffers were prepared with millipore water. Aqua ad iniectabilia (Baxter, Unterschleissheim.
Germany) was used to take up DNA pellets and prepare small amounts of aqueous solutions.
2.1.2 Labware
All  reusable  labware  was  autoclaved  before  use.  Plasticware  was  ordered  from  BD
Biosciences (Heidelberg, Germany) or Eppendorf (Hamburg, Germany).
2.1.3 Kits
Blood & Cell Culture DNA Maxi-kit (Qiagen, Hilden, Germany)
DNeasy tissue kit (Qiagen)
QIAquick PCR purification kit (Qiagen)
QIAGEN Plasmid Mini kit (Quiagen)
QIAquick gel extraction kit (Quiagen)
Chromatin Immunoprecipitation (ChIP) Assay Kit (Upstate/Biomol, Hamburg, Germany)
2.1.4 Vectors
pCR®2.1-TOPO® vectors from the TOPO TA cloning® system (Invitrogen) were used.
2.1.5 Bactrial strains
One Shot® TOP10F' competent cells were used for transformations.
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2.1.6 Oligonucleotides
Oligonucleotides  used  were  designed  with  the  Primer3  program  except  for  primers  for
bisulfite  sequencing,  that  were  designed  manually  and  ordered  from  MWG  Biotech
(Ebersberg, Germany). Stocks were stored as 100 mM solutions in H2O at -20°C.
2.1.7 Antibodies
Antibody Species Company Catalogue
number
anti-acetylated-histone H3 rabbit polyclonal IgG Upstate/Biomol 06-599
anti-FKBP51 (FKBP5) goat polyclonal IgG Santa Cruz Biotechnology, sc-11518
anti-glucocorticoid receptor (Ab-2) mouse monoclonal IgG Oncogene (San Diego, CA, USA) GR32L
anti-MeCP2 C-terminus rabbit polyclonal IgG Upstate/Biomol 07-013
anti-mSin3A rabbit polyclonal IgG Santa Cruz Biotechnology sc-944
anti-SGK1 goat polyclonal IgG Santa Cruz Biotechnology sc-15885
Table 3. Primary antibodies used for ChIP and immunohistochemistry.
Antibody Species Company Catalogue number
FITC-anti-rabbit donkey Dianova (Hamburg, Germany) 111-095-152
Cy3-anti-goat donkey Dianova 705-165-147
Table 4. Secondary antibodies used for immunohistochemistry.
2.1.8 Animals
For preparation of histological sections, C57BL/6 strains mice were used. Primary neurons,
RNA and genomic DNA from brain, was prepared from in house bred CD1 strain mice.
2.1.9 Cell culture
Cell and tissue culture flasks (γ-irradiated and cell culture treated to facilitate binding of the
cells to the plastic surface) were ordered from TPP Biochrom (Berlin, Germany).
DPBS s/o Ca and Mg (BioWhittaker/Biozym, Hess Oldendorf, Germany) was used to wash
cells.
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Media Supplier Other material Supplier
RPMI1640 Invitrogen FBS Biochrom
DMEM BioWhittaker P/S (penicillin/streptomycin) Invitrogen
DMEM:F12 BioWhittaker L-glutamine BioWhittaker
Fungizone Invitrogen
NON-essential amino acids Invitrogen
Trysin Invitrogen
Poly-L-lysine 0.1% in H2O Sigma
Collagen S Type I Roche
DPBS s/o Ca and Mg BioWhittaker
B27 with antioxidants Gibco/Invitrogen
Table 5. Media and other cell culture components.
2.1.10 Cell lines and primary cells
Cell lines were ordered from DSMZ (Braunschweig, Germany) and cultured according the
manufacturer's instructions. Primary mouse cell lines were established from CD1 animals, the
human lymphoblastoid cell line was established (in house) from a male control patient.
2.1.11 Bioinformatics databases and tools
Database name Database type Internet address
Pfam Protein families http://www.sanger.ac.uk/Pfam
Smart Protein families http://smart.embl-heidelberg.de
Prosite Protein families and domains http://www.expasy.org/prosite
BLink Precalculated Blast searches http://www.ncbi.nlm.nih.gov
SSDB Sequence similarity database http://ssdb.genome.jp
Celera Sequence retrieval and analysis http://www.celera.com
Ensembl Sequence retrieveal and analyis http://www.ensembl.org
Unigene Gene-oriented sequence clusters http://www.ncbi.nlm.nih.gov/UniGene
CDD Conserved domain database http://www.ncbi.nlm.nih.gov/Structure/cdd/cdd.shtml
Expasy Protein sequences and analysis tools http://www.expasy.org
PDB Biological macromolecular 3-D structures http://www.pdb.org
HUGE KIAA gene database http://www.kazusa.or.jp/huge
HUGE PPI KIAA protein interaction database http://www.kazusa.or.jp/huge/ppi
Pubmed Medline biomedical articles http://www.pubmed.org
Transfac Transcription factor binding sites http://www.biobase.de
RettBASE Mutation database for MECP2 http://www.mecp2.org.uk
Table 6. Databases used in the different projects of this thesis.
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Tool name Internet address Used in this thesis for
Ensembl Blast http://www.ensembl.org/Multi/blastview Genomic blasts / batch blasts
NCBI Blast http://www.ncbi.nlm.nih.gov/BLAST Masked protein blast
NCBI HomoloGene http://www.ncbi.nlm.nih.gov/HomoloGene Homologous genes
EBI Blast (TBLASTX) http://www.ebi.ac.uk/Blast2/index.html Translated  nt  query  blasted
against translated nt database
ClustalW http://clustalw.genome.jp/ Sequence alignments
ClustalX Windows version ftp://ftp-igbmc.u-strasbg.fr/pub/ClustalX Graphical  representation  of
alignments
Plogo http://www.cbs.dtu.dk/~gorodkin/appl/plogo.html Creation and display of logos
LALIGN http://www.ch.embnet.org/software/LALIGN_form.html Calculation of  identity scores
MATCH http://www.biobase.de Find  transcription  factor
binding sites
GCG package http://www.accelrys.com/products/gcg_wisconsin_package Sequence comparison and 
Primer3 http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi Primer design





Using "MBD" or the MBD of human MECP2 (PDB ID: 1QK9) as query, the NCBI
(http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=Protein), Pfam (release 7), Prosite
(release 17.17) and Smart (version 3.4) databases were screened for proteins with this domain.
The resulting polypeptides were sorted according to their species of origin and additional
identified domains within their sequence. SSDB at GenomeNet was searched with pfm:MBD
as query motif.
MECP2 paralogues:
SSDB at GenomeNet was searched for paralogues with hsa:4204 (the accession number of
MECP2  in  GenomeNet)  as  query and  a  threshold  of  200  to  get  only  the  most  specific
candidates. The resulting data was exported as a list and GenomeNet accession numbers were
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converted into NCBI accession numbers to be comparable to the BLink output list.
For  P51608  (the  accession  number  of  MECP2  in  the  Entrez  protein  database)  the  pre-
calculated blast hits form the BLink database were sorted by taxonomy proximity and score
cut-off of 150 was chosen. All entries for  homo sapiens were exported as a list for further
analysis with Perl scripts.
Mecp2 binding sites:
The genomic region of  FKBP5  and  Fkbp5  were compared in the Ensembl database using
compara tool in the Contig View mode. Furthermore CpG islands, CpG content and Eponine
regions were mapped to the Fkbp5 locus.
The MATCH tool at the Transfac database to find all matches for Transfac matrices in the
genomic region of Fkbp5. The results were compared to the findings in the Ensembl database
and resulted in two regions that  were considered as  possible promoters and covered with
primer pairs for PCR fragments of ~200 bp.
Glucocorticoid receptor response elements in the genomic region of FKBP5 were found by
mapping the Transfac matrix for glucocorticoid binding sites in man, mouse and rat (Transfac
accession number: M00921) to the genomic region of FKBP5. For the resulting 6 regions,
primers were designed and binding of GR was confirmed by ChIP.
2.2.1.2 Blast searches
MBD protein family:
Non-redundant GenBank, high throughput genomic sequences and expressed sequence tag
(EST) databases were searched using BLASTP (expect=10, word size=3, matix=BLOSUM62,
gap  costs=existence11,  extension1)  and  TBLASTN  (expect=10,  word  size=3,
matix=BLOSUM62, gap costs=existence11, extension1) of the NCBI web tools.
The sequence of the human MECP2 MBD (chain A, NCBI accession number: 1QK9A) was
used as a query input. 
TBLASTX (matrix=default, DNA strand=both, exp.thr=default, filter=none, view filter=none,
sensitivity=high)  was  carried  out  applying  the  web  tools  at  the  European  Bioinformatics
Institute (EBI).
BLASTP and BLASTN searches were carried out against the Celera database with settings
corresponding to the ones used in the NCBI blast searches.
KIAA1887 was detected as an MBD protein due to a blast search with MBD of KIAA1461
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(amino acids 11-81) as query for a BLASTP at NCBI using the parameters specified above.
MECP2 paralogues:
To find repetetive regions to be masked in the BLAST search, the sequence of MECP2 was
compared to itself using the Compare program of the GCG Wisconsin package (Version 10.3-
UNIX) (comparison  window  size=25,  stringency=9)  to  calculate  a  matrix  of  points  of
similarity and the DotPlot program to visualize the output.
Of the MECP2 protein sequence (NCBI accession number: P51608) the region aa20 - aa90,
aa160 - aa200 and aa340 - aa400 were masked in a BLASTP (standard settings as defined
above) at NCBI by using the "mask lower case"-option.
2.2.1.3 Sequence comparison
MBD protein family:
Alignments  and  phylogenetic  trees  were  computed  using  the  ClustalW  program  at
GenomeNet with standard settings and the ClustalX program (version 1.8) (Thompson et al.,
1997) for graphical representation. The sequence logo was constructed by means of the plogo
script.  File  formats  were  converted  with  the  GCG  Wisconsin  package  when  necessary.
Sequence comparison between mouse and man was carried out using the LALIGN algorithm
at EMBNET with default settings. Homologues of  KIAA1461, CLLL8  and  KIAA1887  were
identified using the ortholog prediction in the Ensembl database.
Mecp2 target genes:
Sequence analysis was done using the reformat and pileup functions of the GCG Wisconsin
package  to  get  multiple  sequence  alignments  that  could  be  screened  for  the  presence  of
cytosines not modified by the bisulfite treatment.
2.2.1.4 Perl scripts
Several small scripts were written using the script language Perl (version 5.8.0). File formats
were converted to  be suitable  as input  files  for GCG. Accession numbers  of GenomeNet
derived from the  SSDB searches  for  MECP2 paralogues  were  transformed into NCBI-GI
accession numbers. With the help of a Perl script, sequences files formats of bisulfite treated
and cloned DNA fragments were sorted and converted to be suitable as input files for the
GCG PileUp program.
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2.2.2 cDNA microarrays
2.2.2.1 Microarray production
Murine cDNA clones (n = 10,080; arrayTAG clone collection) were purchased from LION
Bioscience (Heidelberg, Germany). These cDNA clones map to the 3´ end of the respective
transcript and are sequence-verified and sequence-specific (i.e. do not contain poly-A tails or
large  repeats).  An  additional  3510  murine  cDNA  clones,  representing  brain-expressed
transcripts were obtained from the resource center of the German Human Genome Project
(RZPD,  Berlin,  Germany)  and  3  murine  cDNA  sequences  were  amplified  with  specific
primers.  As negative  controls  17 plant  cDNA sequences,  amplified with specific  primers,
were included as duplicates resulting in 34 plant derived cDNAs on the chip. This resulted in
a set of 13,627 clones that were used for the array and could be kept as plasmid inserts, stored
as E. coli glycerol stocks.
For the array production, clone inserts were amplified by PCR (Tables 8, 9). Primers Lion 3'
and Lion 5' were used for clones from LION bioscience, and primers M13for and M13rev
were  used  for  RZPD clones,  as  well  as  for  the  3 murine  and the  plant  clones.  All  PCR
products were evaluated by agarose gel electrophoresis (see section 2.2.4.5). These steps were
automated  with  a  robot  (Tecan  Genesis  Workstation  200,  Crailsheim,  Germany)  in
combination with a temperature controlled hotel (automatic incubator cytomat 6002, Hereaus,
Hanau, Germany).
2 μl of the bacterial template clones stored in 96-well microtiter plates were mixed with 50 μl
PCR master mix in a new 96-well microtiter plate.
Primer name Primer sequence Annealing temperature Annealing time
Lion 3' 5'-tcgagcggccgcccgggcaggt-3' 68 °C 30 sec
Lion 5' 5'-agcgtggtcgcggccgaggt-3' 68 °C 30 sec
M13for 5'-gtaaaacgacggccag-3' 54 °C 90 sec
M13rev 5'-caggaaacagctatgac-3' 54 °C 90 sec
Table 8. Pimer pairs used for the amplification of plasmid inserts for the array production.
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PCR master mix 
(total volume = 50 μl)
94°C 3 min 1 94°C 5 min 1 5 μl 10 x Perkin Elmer PCR buffer
94°C 30 sec 94°C 45 sec 10  μl dNTPs (1 mM each)
68°C 30 sec 35 54°C 90 sec 35 2 U MPI Taq (made in house) (10 U/μl)
72°C 50 sec 72°C 2 min 2 μl forward primer (10  μM)
72°C 10 min 1 72°C 10 min 1 2 μl reverse primer (10 μM)
4°C infinite 1 4°C infinite 1 29 μl nuclease free water
Table 9. PCR conditions used for the amplification of cDNAs for the microarray.
Finished plates were stored in the temperature controlled hotel until use for PCR amplification
in a PrimusHT multiblock thermal cycler (MWG Biotech) or alternatively were frozen at -20°
C for later amplification.
The same robot could be used to mix 5 μl of PCR product from readily amplified plates with 5
μl  of gel-loading buffer in a new 96-well  microtiter  plate.  This mixture was analyzed on
agarose gels using the Roboseq 4204S system (MWG Biotech) for gel loading.
45  μl (remaining after the agarose gel analysis) of each PCR product were combined with 2.5
volumes  EtOH  and  0.1  volumes  sodium  acetate  3  M  pH=5.  DNA  was  precipitated  by
incubation at -80°C for 30 min, and centrifugation at 20,000g for 15 min at 4°C. The pellet
was resuspended in 18 μl 3 x SSC and 8 μl of each product were transferred to a well in a
384-well  plate  with  a  Multimek  96/384 robot  (Beckman  Coulter,  Krefeld,  German).  The
resulting 384-well plates were stored at -20°C until further use.
PCR products purified and processed in such a manner were printed on Corning GAPS II
slides  by  using  a  robotic  spotting  device  (SDDC-2  MicroArrayer,  ESI,  Toronto,
Canada/ChipWriter  Pro,  Bio-Rad,  Munich,  Germany)  with  SMP3  pins  from  TeleChem
International (Sunnyvale, CA).
2.2.2.2 Microarray hybridization and washing
Total RNA from the brain of a 74 day old Mecp2-/y animal with late symptoms (gait ataxia,
hind limb clasping, breathing irregularities, uneven teeth, small stature) and a  wt male litter
mate was sent by our collaborators in Edinburgh. Labeled target cDNA was generated by
direct incorporation of fluorescent nucleotide analogs in a reverse transcription reaction. Total
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RNA (75 μg of each sample) was used in an oligo dT primed reaction in the presence of
100  μM  Cy3-  or  Cy5-dUTP  (Amersham  Pharmacia  Biotech  Europe  GmbH,  Freiburg,
Germany), 200 μM dTTP and  500 μM dATP, dCTP, and dGTP. The labeled cDNA was
purified using the Qiaquick PCR purification kit. Labeled cDNA targets were resuspended in
hybridization solution (50% formamide, 6 x SSC, 0.5% SDS, 5 x Denhardt´s solution), to
which  l  μl  poly-dA (10  μg/μl)  and  l  μl  mouse  Cot-1  DNA (20  μg/μl)  were  added.  The
resulting reaction solution was concentrated to 35 μl, denatured at 95°C for 3 min and snap-
cooled on ice. Hybridization took place under a coverslip at 42°C for 16 hours. The slides
were washed at room temperature in 0.2 x SSC and 0.01% SDS for 5 min, followed by two
washing steps in 0.2 x SSC for 5 min each. In total, two co-hybridizations (Mecp2-/y versus wt
brain cDNAs) were performed with dyes swapped in the repeat experiment. 
2.2.2.3 Image aquisition and data analysis
Fluorescence intensities of Cy3 and Cy5 were measured separately at 532 and 635 nm with a
laser scanner (Affymetrix 428 Array Scanner, Affymetrix). The resulting 16-bit data files were
imported  into  Microarray  Suite  image  analysis  software  (version  2.0),  which  runs  as  an
extension of IPLab Spectrum software (Scanalytics, Fairfax, VA). Raw spot intensities of Cy3
and Cy5 were locally background subtracted by the MicroArray Suite software. Empty spots
and spots carrying plant gene sequences were excluded from further analysis. Each dye swap
experiment was normalized by applying variance stabilization (Huber  et al., Bioinformatics
2002)  using  the  vsn  package  of  bioconductor  (http://www.bioconductor.org).  Means  of
normalized  log-products  and  log-ratios  of  each  dye swap  experiment  pair  were  used  for
further  analysis.  Normalization  procedures  were  performed  using  R  (http://cran.R-
project.org).  The  data  sets  of  two co-hybridization  experiments  with dye swap were first
quality checked for pin- and PCR plate-specific effects by local regression according to each
pin  or  PCR  plate.  Furthermore,  background intensities  across  the  slide  were  checked for
homogeneity. Spots  with  local contaminations  were excluded from further  analysis.  Local
background-subtracted raw intensities on a logarithmic scale were normalized by Analysis of
variance between groups (ANOVA) using the MATLAB code, with slight modifications. The
underlying ANOVA model we applied was:
log(yijkg ) =  μ + Ai + Dj + Vk + Gg + (AG)ig + (V G)kg + ε ijkg 
i=1,2; j=1,2; k=1,2; g=1 ,… ,13627; 
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(where y is the log intensity of each channel, μ is the overall mean, A is the overall array
effect, D is the overall dye effect, V is the overall variety effect, G is the overall gene effect,
AG describes array gene interactions and VG describes variety-gene interactions). Genes were
then sorted according to their variety-gene differences ((V G)k=sample, g - (V G)k=control ,
g ), which is an estimate of the log ratio of the sample versus control normalized intensities.
Clones showing more than 2-fold changes were considered relevant. All data analyses were
performed using MATLAB, Version 6.0.0.88, Release 12, MathWorks Inc., MA, USA.
2.2.3 Cell culture
2.2.3.1 Coating of culture flasks
Poly-L-lysine 0.1% in H2O was diluted 1:10 with sterile H2O. This solution was applied to cell
culture flasks and incubated at room temperature for 5min. After three washes with sterile
H2O,  flasks  were  left  to  dry  under  sterile  conditions.  Poly-L-lysine  coated  flasks  were
incubated with collagen S Type I solution diluted 1:100 in Neurobasal medium for 2 h at 37°C
followed by 3 washes with DBPS, just before use.
2.2.3.2 Primary fibroblasts
Primary fibroblasts were prepared from adult CD1 mice (in house breeding facility): Dermis
from dorsal skin was dissected, washed in sterile DPBS s/o Ca and Mg several times, placed
in trypsin and chopped into pieces of 1-2 mm diameter. The pieces were placed in a 25 cm2
cell culture flask and left to attach for three to four hours. Once the cells had attached to the
flask, 5 ml DMEM:F12 medium 1:1 (BioWittacker) supplemented with 20% FBS (Biochrom,
Berlin, Germany), P/S (100 U/ml, 10 μg/ml respectively) (Invitrogen), L-glutamine (2 mM)
(BioWhittaker)  and  Fungizone  (2.5  μg/ml)  (Invitrogen)  were  added  carefully.  Cells  were
grown for 1 week to  a confluency of 95% before passaging.  For passaging,  medium was
removed,  cells  were  washed  with  sterile  DPBS  s/o  Ca  and  Mg  twice  and  separated  by
incubation in 2 ml trypsin (Invitrogen) for 5 min at 37°C. The trypsin solution containing the
cells was mixed with 13 ml fresh medium and plated in a 75 cm2 flask. This step was repeated
after 5 days to get a 150 cm2 cell culture flask with primary fibroblasts. Once the cells had
reached 95% confluence, they were harvested for DNA isolation.
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2.2.3.3 Lymphoblastoid cell line
Eppstein-BarrVirus  (EBV)  transformed  primary  lymphoblastoid  cells  were  grown  as
suspension cultures in RPMI1640 medium supplemented with 10% FBS,  P/S (100 U/ml, 10
μg/ml), and L-glutamine (2 mM) and passaged 1:2 every 3 days..
2.2.3.4 Primary neurons
Heads  of  mouse  embryos from a  litter  between  embryonic  days 16  to  18  were  carefully
prepared and placed in DPBS s/o Ca and Mg + 6 g/l glucose (Sigma). After cutting off the
snout, brains were squeezed out and placed on ice in DPBS s/o Ca and Mg with 10% FBS and
6  g/l  glucose  until  further  use.  Single  cells  were  isolated  mechanically  by  pipetting,
fragmented with a cell strainer (40 μm; BD Falcon, Heidelberg, Germany), and centrifuged at
700 rpm for 1 min with slow acceleration and brake. The cell pellet was resuspended in 2ml
medium (see below). The cell  concentration was determined with a CASY1 Cell  Counter
(Schärfe System, Reutlingen, Germany). 1.5 x 107 cells were plated per 150 cm2 cell culture
flask coated with  collagen S Type I  and poly-L-lysine. The medium was changed every 3-4
days. After 7-10 days, cells were harvested for ChIP or treated with glucocorticoids for ChIP.
For 500 ml medium, 485 ml Neurobasal Medium (Invitrogen), 10 ml B27 with antioxidants
(Gibco; mit  Antioxidantien), 5 ml P/S (100 U/ml, 10 μg/ml respectively), (Invitrogen) and
1.25 ml L-glutamin (2 mM) were used. 
2.2.3.5 Glucocorticoid treatment of primary neurons
Stock  solutions  of  dexamethasone  (Sigma-Aldrich)  10  mM  in  EtOH  and RU-486
(Mifepristone, Sigma-Aldrich) 100 mM in EtOH were prepared. Twenty hours before harvest,
respective amounts of the stock solutions (Table 10) were added to the culture medium of
primary neuron cultures. EtOH was added to negative control cultures to consider potential
effects of EtOH on the primary neurons.
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Culture Dexamethasone (10mM in EtOH) RU-486 (100mM in EtOH) EtOH 100%
EtOH - - 2.5 μl
Ru - 1.25 μl 1.25 μl
RU, Dex 1.25 μl 1.25 μl -
Dex 1.25 μl - 1.25 μl
Table 10. Scheme depicting the amounts and concentrations of chemicals used for glucocorticoid
treatment experiments.
2.2.3.6 CCRF-CEM
CCRF-CEM cells were grown in RPMI1640 medium supplemented with 10% FBS,  P/S (100
U/ml, 10 μg/ml), L-glutamine (2 mM) and Fungizone (2.5 μg/ml), according to manufacturer's
instructions. Saturated cultures were split 1:2 every 2-4 days by detaching cells in with trypsin
and  reseeding  in  new  cell  culture  flasks  with  fresh  medium  as  described  for  primary
fibroblasts. CCRF-CEM cells were harvested at 95% confluence for RNA isolation.
2.2.3.7 NEURO-2A
NEURO-2A cells were grown according to manufacturer's instructions in DMEM medium
with 10% FBS,  P/S (100 U/ml, 10 μg/ml), L-glutamine (2 mM), 1% NON-essential amino
acids (NEAA) and Fungizone (2.5 μg/ml). Cells were grown to 85% confluence and split 1:4
once a  week as  described for  primary fibroblasts.  Cells  were harvested at  85% for DNA
isolation and ChIP.
2.2.4 Molecular biology techniques
2.2.4.1 DNA isolation
General:
Genomic DNA from CCRF-CEM cells and primary fibroblasts was isolated with the Qiagen
Blood Maxi-KIT following the manufacturer´s instructions.
Genomic  DNA  from  CD1  mouse  brains  was  isolated  DNeasy  tissue  kit  following  the
manufacturer´s instructions.
Mecp2 binding sites:
After  ChIP,  DNA  was  isolated  using  the  phenol/chloroform  extraction  followed  by
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precipitation  of  the  DNA.  DNA  containing  solutions  were  mixed  1  volume  of
phenol:chloroform 1:1, carefully inverted for 5 min, and centrifuged for 10 min at 4000rpm in
a table centrifuge. The upper aqueous phase was transferred to a new tube, mixed with 1
volume of chloroform, carefully mixed for 5 min and centrifuged for 10 min at 4000rpm. The
upper phase was then transferred to a new tube and combined with 2.5 volumes of ice cold
EtOH, 1/10 volume sodium acetate and 1 μl glycogen. After inversion of the tube, the solution
was cooled down for 30 min at -80°C (alternatively overnight at -20°C) and then centrifuged
for 45 min at 4°C. The resulting DNA pellet was washed with 70% EtOH (in water) briefly
and  centrifuged for 45 min at 4°C. The supernatant was discarded and the pellet dried in an
concentrator 5301 speedvac (Eppendorf) at 37°C after puncturing the lid of the tube with a
needle (to prevent contaminations as far as possible). The dried pellet was redissolved in 50 μl
ultra pure H2O and subjected to SR1 and SR2 amplifications (see section 2.2.4.8.)
2.2.4.2 RNA isolation
Total RNA from CCRF-CEM cells was isolated using the Trizol reagent (Invitrogen). All
plastic- and glassware used was rinsed with water containing 0.05% DEPC and autoclaved
before use to inactivate RNAses. The cell pellet was dissolved carefully in 10 ml Trizol,
transferred to and 30 ml tube and incubated at RT for 5 min 2 ml chloroform were added and
the solution was mixed vigorously for 15 sec, incubated at RT for 2-3 min followed by a
centrifugation step at 4°C and 5000rpm for 20 min. The supernatant was transferred to a new
tube and well mixed with 5 ml isopropanol. After incubation at RT for 5 - 10 min the solution
was centrifuged at 4°C and 10000rpm for 10 min. The supernatant was discarded and the
pellet washed with 70% EtOH (prepared with RNAse-free water) followed by a centrifugation
at 4°C at 10000rpm for 5 min. The resulting pellet was dried and dissolved in 500 μl RNAse-
free water. RNA concentration was measured using a Ultrospec 3100pro UV/VIS photometer
(Amersham) and RNA quality was checked on an 1% agarose gel.
2.2.4.3 Standard PCR
Standard  PCR  was  performed  in  an  GeneAmp  PCR  System  9700  cycler  (Applied-
Biosciences, Darmstadt, Germany) with Perkin-Elmer Taq polymerase (Applied-Biosystems).
If not indicated otherwise, the following PCR conditions were used:
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Step Temperature Time Cycles PCR mix
Initial denaturation 94°C 5 min 1 2 µl template
Denaturation 94°C 45 sec 5 µl 10x reaction buffer 
Annealing Primer-specific 1 min 35 1 µl dNTPs (10 mM each)
Elongation 72°C 1 min 1 µl forward primer (1 µM)
Final elongation 72°C 7 min 1 1 µl reverse primer (1 µM)
Storage 4°C infinite 1 0.5 µl  PE-Taq polymerase 
39.5  µl H2O
Table 11. Standard PCR temperature profile and PCR mix. 
Touchdown PCR was applied for products that proved difficult to amplify:
Step Temperature Time Cycles PCR mix
Initial denaturation 94°C 5 min 1 2 µl template
Denaturation 94°C 45 sec 5 µl 10x reaction buffer 




1 µl dNTPs (10 mM each)
Elongation 72°C 1 min 1 µl forward primer (1 µM)
1 µl reverse primer (1 µM)
Denaturation 94°C 45 sec 0.5 µl  PE-Taq polymerase 
Annealing Primer-specific 1 min 30 39.5  µl H2O
Elongation 72°C 1 min
Final elongation 72°C 7 min 1
Storage 4°C infinite 1
Table 12. Touchdown PCR temperature profile and PCR mix. TA is the primer specific annealing
temperature.
2.2.4.4 cDNA synthesis and subsequent gene-specific PCR (RT-PCR)
RNA (20 µg) isolated from total mouse brain, CCRF-CEM cells or lymphoblastoid cells using
the Trizol reagent (Invitrogen) (see section 2.4.2) was subjected to a reverse transcriptase
reaction in the presence of 25 ng/ml oligo(dT) and 2.5 mM dA/C/G/TTP  with 10 U/ml SSII
reverse transcriptase  and without enzyme in negative control reactions. The RNA in 17 µl
RNAse-free water was mixed with the oligo-dTs and the dNTPs to a final volume of 23 µl
and incubated at 65°C for 5 min followed by 5 min on ice. After addition of 8 µl 5 x first-
strand Buffer, 4 µl 0.1 M DDT , 1 µl RNAsin, and 4 µl SSII reverse transcriptase (200 U/µl),
the mixture was  incubated for 55 min at 42°C and for 10 min at 70°C. 
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2 µl of the mixture were used in gene-specific PCR reactions or alternatively, the resulting
cDNA was purified with the QIAquick PCR purification kit and 200ng of the purified cDNA
were subject to gene-specific PCRs.




mFkbp5_exon1_exp_for 5’-gcggcgacaggtcttcta-3’ 5’-gctttgataacctggccttg-3’ 56°C 1 min
KIAA1887_exon_6 5’-cagaccccctactgtatttc-3’ 5’-caaaaggttaaagcttccat-3’ 49°C 1 min
KIAA1461 5'-ctagaccatgggaaaaatgt-3' 5'-acttggagactgctcctcta-3' 51°C 1 min
β-actin 5’-tgaaccctaaggccaaccgtg-3 5’-gctcatagctcttctccaggg-3’ 57°C 45 sec
Table 13. Primers used for the amplification of gene specific PCR products from cDNA templates.
Standard PCR conditions were applied except for β-actin where the annealing time was only 45 sec.
2.2.4.5 Agarose gel electrophoresis
1% agarose gels were used to separate DNA or RNA samples by gel electrophoresis. 
Gel composition: 1% w/v ultra pure agarose in TBE buffer (0.1 M Tris, 0.1 M boric acid, 2
mM EDTA). 0.5 μl/ml EtBr was added to the gels to make visualization of the DNA via UV-
light possible. Before loading, samples were supplemented with at least 0.5 volumes of gel
loading buffer composed of 0.25 % bromphenol blue, 0.25 % xylene cyanol FF, and 30 %
glycerol. 2 different DNA size markers were used depending on the size of the fragment sizes
expected: pUC mix 8 (MBI Fermentas, St. Leon-Rot, Germany) with a range from 110 bp -
1116 bp and Lambda DNA / EcoR1+HindIII 3 (MBI Fermentas) with a range from 564 bp to
21226 bp. Voltage (80 -150 V) and running times (15 - 45 min) depended on the expected
fragment sizes.  For visualization,  the E.A.S.Y Win32 gel documentation system (Herolab,
Wiesloch, Germany) was used. 
2.2.4.6 Sequencing
For sequencing of PCR products,  the fragments were purified by gel extraction using the
QIAquick gel extraction kit. Using the TOPO TA cloning kit, PCR products were then ligated
into a pCR2.1-TOPO vector. For transformation, 'One shot competent E. coli cells'  were used
according to the manufacturer´s instructions.  E. coli cells were grown overnight at 37°C on
selective plates (containing 50 μg/ml ampicillin) and supplemented with 50 μl 4% X-Gal and
50 μl IPTG (0.1M). White clones were picked and grown in 2 ml LB medium (Tryptone 10
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g/l, NaCl 10 g/l, yeast extract 5 g/l) with 50 μg/ml ampicillin overnight. Plasmid DNA for
sequencing was isolated using the Qiagen plasmid mini kit according to the manufacturer´s
instructions. Per 100bp to be sequenced 10 ng DNA were required and subject to sequencing
PCR with M13rev primers:
Step Temperature Time Cycles PCR mix                        
Initial denaturation 94°C 2 min 1 2 µl Dye Terminator (made in house)
Denaturation 94°C 20 sec 10 pmol primer
Annealing 54°C 15 sec 30 7 µl DNA solution
Elongation 60°C 4 min
Table 14. Temperature profile and PCR mix for sequencing reactions with M13 primers.  After the final
elongation step, the PCR plates are stored on ice.
The PCR-reaction product was precipitated by addition of 25 µl  EtOH. The solutions were
mixed gently and the incubated in the dark for 10 min at RT. After a centrifugation step for 45
min at 4000 rpm at RT the obtained pellet was washed with 100 µl 70% EtOH, mixed gently
and centrifuged for 30 min at 4000 rpm at RT. The supernatant was discarded, the pellet dried
and the obtained fragments separated and analyzed on an ABI377 DNA sequencer.
2.2.4.7 Northern blotting
A cDNA fragment of KIAA1461 was PCR-amplified with exon specific primers KIAA1461
(see section 2.2.4.4) and human genomic DNA from mouse primary fibroblasts as template
using standard conditions. For KIAA1887 a cDNA fragment was PCR-amplified with exon 6
specific primers KIAA1887_exon_6 (see section 2.2.4.4) and cDNA from a lymphoblastoid
cell line as template using standard conditions. A cDNA fragment of β-actin amplified with
primers β-actin (see section 2.2.4.4) was used as a loading control. These probes were
radioactively labeled with 32P-dCTP in a random prime reaction and hybridized in
ExpressHyb solution (CLONTECH, Palo Alto, CA, USA) to a human multiple tissue
Northern blot (CLONTECH, Palo Alto, CA, USA) for 16 h at 65°C. Washing was performed
in 2 × SSC / 0.1% SDS at 65°C for 10 min. Signals were detected with a PhosphorImager
(Amersham Biosciences, Freiburg, Germany).
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2.2.4.8 Chromatin immunoprecipitation
Chromatin  immunoprecipitation  was  performed  with  NEURO-2A  cells  to  establish  the
procedure and test primers pairs. Final experiments were carried out with brain tissue and
primary neurons.
NEURO-2A cells and primary neurons (generally one 150cm2 flask was used per condition or
treatment) were crosslinked by addition of 1% formaldehyde (Roth) and incubation at 37°C
for 10 min to the culture medium. Subsequent quenching was achieved by adding glycine
(Merck) to a final concentration of 125 mM.
Frozen  total  brain  tissue  was  pulverized  with  a  mortar,  taken  up  in  10  ml  DMEM
(BioWhittaker) with protease inhibitors (1 tablet Complete Mini Cocktail (Roche) per 10 ml
solution as well as 2 mM PMSF) and incubated for 10 min at 37°C in the presence of 1%
formaldehyde.  Formaldehyde  treatment  was  quenched  by  addition  of  glycine  to  a  final
concentration of 125 mM.
The Chromatin immunoprecipitation protocol was based on  the Upstate Biotechnology ChIP
kit protocol with the following modifications:
Sonication was carried out with a  Branson Sonifier 450 (Branson, Danbury, CT, USA) was
used at output control level 5 with 100% duty and pulses of 30 sec. The number of pulses
depended on the cell type and the amount of chromatin in the sample. After sonication, DNA
fragment sizes 5 µl of the sheared material was loaded on a 1% agarose gel to check the
fragment  sizes.  If  the  smear  on  the  gel  was  >  200  -  1000  bp,  additional  shearing  was
necessary.
DNA concentration  in  the  sheared  chromatin  was  determined  with  an  Ultrospec  3100pro
UV/VIS photometer (Amersham) and samples were diluted to 100 µg/ml DNA and split into
portions  of  1  ml  in  1.5  ml  eppendorf  tubes.  The  tubes  were  either  subjected  to
immunoprecipitation or stored at -20°C until further use.
The  chromatin  was  then  subjected  to  immunoprecipitation  using  antibodies  specific  to
acetylated histone H3, mSin3A, the MeCP2 C-terminus or the DNA binding domain of  GR
according  to  the  Upstate  ChIP  kit  protocol.  To  reduce  unspecific  binding  in  the
immunoprecipitation, the pre-clearing was performed with 75 µl (instead of 60 µl) Protein A
agarose / Salmon sperm DNA and all washing steps described in the Upstate protocol were
carried out twice. After reverse crosslinking, protein digestion, and DNA isolation, fragments
were dissolved in 50 µl aqua ad iniectabilia and subjected to a two-step DOP-PCR. In the first
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step 20 µl template were ligated to degenerated SR1 primers in a PCR reaction. In the SR2
PCR the fragments ligated to the SR1 primer were amplified using the SR2 primer.
SR1 SR2
Primer 5´-gccgtcgacgaattcnnnnnnnnn-3´
( where n can be any base a, g, t or c)
5´-gccgtcgacgaattc-3´
Template 20 µl purified ChIP product 2 µl  SR1 -PCR product 
PCR mix 20 µl template
1 µl dNTPs (10 mM each)
5 µl 10x reaction buffer (Perkin-Elmer)
2 µl SR1-primer (10pMole/ul)
2 µl PE-Taq (Perkin-Elmer)
20 µl ultra pure H2O
2 µl template
5  µl  10  x  reaction  buffer  (Perkin-
Elmer)
1 µl dNTPs (10 mM each)
2 µl primer SR2
2 µl PE-Taq (Perkin-Elmer)
38 µl ultra pure H2O
Table 15. PCR mix for SR1 and SR2 reaction.
SR1 SR2
SR1 temperature profile SR2 temperature profile
Step Temperature Time Cycles Temperature Time Cycles
1 94°C 5 min 1 94°C 5 min 1
2 94°C 30 sec 94°C 30 sec
3 15°C 60 min 50°C 45 sec 60
4 20°C 45 min 72°C 1 min
5 25°C 30 min 72°C 4 min 1
6 30°C 30 min 4°C infinite 1
7 35°C 20 min 5
8 40°C 1 min
9 45°C 30 sec
10 50°C 30 sec
11 55°C 20 sec
12 60°C 20 sec 
13 60°C 7 min 1
14 4 °C forever 1
Table 16. Temperature profile for SR1 and SR2 PCR reaction.
2 µl of the DNA samples amplified by SR1 and SR2 reactions were subject to standard PCR
amplifications with primers specific for binding sites of MECP2 and GR with the following
annealing temperatures and cycle numbers.
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Primer
name
Forward primer Reverse primer Template Annealing
temperature
m1_0 5‘-tgctcccttagattcatcccacac-3‘ 5‘-ccactggctccgatacacattctc-3‘ 2 µl 55°C
m1_4 5‘-agtacccaacagaggtcaga-3‘ 5‘-tgtggatacaaaatattcca-3‘ 2 µl 49°C
m2_1 5‘-tcttggccttacctttaat-3‘ 5‘-agttctcagggacttttcag-3‘ 2 µl 49°C
m2_2 5‘-acacagaaacaataacaaaagc-3‘ 5‘-tcaacaatatggctgtagga-3‘ 2 µl 49°C
m2_4 5‘-gcacaatgctggactagata-3‘ 5‘-tttaatgtgctcagtgcttc-3‘ 2 µl 49°C
Fkp 5‘-agccacggtcctagatgagagc-3‘ 5‘-gtgtgtgaaggagagtggcagaac-3‘ 2 µl 60°C
Fkp1 5‘-tgctcccttagattcatcccacac-3‘ 5‘-ccactggctccgatacacattctc-3‘ 2 µl 60°C
GRE_2 5‘-tccaaagtccctatgtaccc-3‘ 5‘-tggtccacaaacatacacg-3‘ 2 µl 53°C
Table 17. Primer used to amplify DNA fragments precipitated by ChIP.
Three buffers, not included the Upstate ChIP kit, were prepared in the lab:
Nuclei extraction buffer Nuclei wash buffer Re-suspension buffer
HEPES 10 mM 10 mM
Sucrose 320 mM 320 mM
MgCl2 5 mM 5 mM
Tris pH= 7.5 15 mM
EDTA 1 mM
NaCl 150 mM
Triton X-100 1% 0.5%
Millipore H2O in millipore H2O in millipore H2O in millipore H2O
pH=7.4 adjusted with NaOH pH=7.4 adjusted with NaOH
Table 18. Composition of the ChIP buffers not included in the Upstate ChIP Kit.
2.2.4.9 Bisulfite sequencing
Genomic DNA from brain was isolated using the DNeasy tissue kit  (see section 2.2.4.1).
Conversion  of  genomic  DNA  by  sodium  bisulfite  was  performed  as  described  in  the
CpGenome DNA Modification Kit manual (Chemicon, Temecula, USA). Regions of interest
were amplified from the bisulfite treated genomic DNA with specific primers. Amplification
was performed using standard PCR conditions or touchdown PCR (TD) and fragments were
cloned and sequenced.
53
2. Materials and Methods
                                                                                                                                                                                                                                                           
Primer name Forward primer Reverse primer Template
FKB5musP1_4bis 5‘-aatacccaacaaaaatcaaaaaaaa-3‘ 5‘-tgtggttataaaatattttataggtaat-3‘ 3 µl
FKB5_2_1meth_new 5‘-cacacttctataaccttacctttaat-3‘ 5‘-gtttttagggattttttaggtgtgtt-3‘ 3 µl
FKB5_2_2meth_new 5‘-aaattaaaacacaaaaacaataacaaaaac-3‘ 5‘-ttgtttttttttaataatatggttgtagga-3‘ 3 µl
mFKB5_2_4_me4for/
LH1rev
5‘-gtataatgttggattagataattagggaattag-3‘ 5‘-tttaatatactcaatacttgtatcctattata-3‘ 3 µl
mFKB5_2_4_me5for/
LH2rev
5‘-atttagtttagtataatgttggattagata-3‘ 5‘-cctaatacctttaatatactcaatacttc-3‘ 3 µl
Table 19. Primers used for bisulfite sequencing of the regions 1_4, 2_1, 2_2, and 2_4. The touchdown PCR
protocol was applied with an annealing temperature of 53°C and an annealing time of 1 min and 15 sec.
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3. Results
3.1 MBD protein family
3.1.1 Objective
Bioinformatics  approaches  to  find  gene  products  with  certain  properties  have  become
fashionable since the publication of the complete human genome in 2001 (Lander et al., 2001,
Venter et al., 2001) and its free availability to researchers. This is particularly true for families
of proteins. A protein family is a group of proteins that share at least a part of their amino acid
sequence – usually a domain. Protein domains are defined as independent and often globular
folding units within a three-dimensional protein structure. Many databases have been created












Table 20. Protein domain and protein family databases. Of these databases, Pfam, Prosite, and Smart proved
to be very useful for this study.
To this end, the aa sequence of known domains are defined as motifs using sophisticated
mathematical algorithms such as Hidden Markov Models (HMMs). Proteins are grouped into
a protein family if they comprise a certain motif, that is to say, contain an aa sequence similar
(each database has its  own criteria  for these similarities)  to a motif  in the database.  This
implies, that one protein can belong to several protein families if the corresponding motifs are
present in its sequence. Most of these databases use an alignment of polypeptide sequences
known to represent a certain motif in order to create a standard profile that is then applied to
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screen other databases for the occurrence of a similar sequence.
In this  project,  the  MBD motif  from the  Pfam database  was  used  to  look  for  additional
proteins that could potentially bind methylated CpGs.
3.1.2 Human MBD proteins
The MBD of human MECP2 served as query sequence to search for new members of the
MBD protein family. Initial standard BLAST searches of the NCBI, Celera, and SwissProt
databases resulted only in five MBD proteins (MECP2, MBD1, MBD2, MBD3, and MBD4)
which had previously been described and studied intensively.
However,  the search of protein domain family databases (CDD, Pfam, Prosite and Smart)
revealed  six  additional  proteins,  i.e.  BAZ2A/TIP5,  BAZ2B,  CLLD8/SETDB2,  SETDB1,
KIAA1461, and KIAA1887 with similarities to the MBD of MECP2. Due to the results of this
study, KIAA1461 has been named MBD5 and KIAA1887 is now called MBD6. The Pfam,
Smart, and Prosite database use HMMs to detect motifs in amino acid sequences. This method
is more sensitive than standard sequence similarity searches such  as BLAST and FASTA,
which explains why our BLAST searches did not detect these additional proteins. An MBD
has been described in CLLD8, SETDB1, and BAZ2A/TIP5 earlier (Mabuchi  et al.,  2001,
Schultz  et al., 2002, Strohner  et al., 2001) without including these proteins into the MBD
protein family.
Nine of the eleven MBD-containing protein sequences could also be detected by screening the
Sequence Similarity DataBase (SSDB) (Kanehisa et al., 2002) at GenomeNet. The cDNAs for
KIAA1461/MBD5  and  KIAA1887/MBD6  were  not  found  since  the  KEGG  database
underlying the SSDB contains only confirmed but not predicted protein sequences. Table 21
summarizes all proteins identified, their domains, the position of the MBDs and the search
method by which the protein was found.
The MBD amino acid sequences of the five previously published proteins as well as the MBD
sequence of  the six newly described human MBD protein family members were aligned to
analyze the conservation of amino acids across the different proteins (Fig. 9). 
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Accession No.a) Name Search method /databaseb) Domainsc) MBD positiond)
P51608 MECP2 a, b, c, d, e, f, g, ac, bc, cc 96-149
Q9UIS9 MBD1 a, b, c, d, e, f, g, ac, bc, cc zf-CXXC 7-59
Q9UBB5 MBD2 a, b, c, d, e, f, g, ac, bc, cc 151-204
O95983 MBD3 a, b, c, d, e, f, g, ac, bc, cc 8-60
Q9Z2D7 MBD4 a, b, c, d, e, f, g, ac, bc, cc HhH-GPD 82-135
Q9UIF9 BAZ2A/TIP5 e, f, g AT-hook, DDT, PHD, bromodomain 526-577
Q9UIF8 BAZ2B e, f, g DDT, PHP, bromodomain 549-600
Q15047 SETDB1 e, f, g SET 597-653
Q96T68 SETDB2 e, f, g SET 162-216
Q9P267 MBD5 e, f PWWP 21-79
Q96Q00 MBD6 e, f 304-456
Table  21  Summary  of  the  human MBD  polypeptides. a)  Accession  numbers  according  to  the  SwissProt
database. b) a = BLASTP, b = TBLASTN, c =TBLASTX, d = PSI-BLAST, e = Pfam, f = Ncbi, g= SSDB, ac =
BLASTP in Celera database, bc = TBLASTN in Celera database, cc = TBLASTX in Celera database. c) domain
nomenclature according to the Pfam database, all sequences contain an MBD in addition.  d) position in amino
acid sequence.
Fig. 9. Alignment of the human methyl-CpG-binding proteins according to Swissprot. ClustalX alignment
of the original human MBDs (above) and all MBDs (below). Columns are colored by conservation and property
(Thompson  et  al.,  1997).  Residue  conservation above each column indicates:  “*” completely conserved;  “:”
favored substitutions; “.” weakly favored substitutions. A quality graph is depicted below each alignment.
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The  analyses  of  all  11  polypeptides  implicate  a  small  number  of  highly  conserved  and
apparently essential amino acids within the MBD domain, especially the proline at position 36
(P36) as well as glycine 38 (G38) and tyrosine 50 (Y50). Five positions with conservative
substitutions can be found (indicated by ":").
Fig.  10  depicts  a  sequence  logo  derived  from  the  alignment  of  all  eleven  human  MBD
sequences. 
Fig. 10. Sequence logo of the eleven human MBD sequences. The height of the letters relative to the other aa,
corresponds to the frequency of the amino acid at its position.  The total height of each stack stands for the
information present at this position, measured in bits. Top letters represent the consensus sequence. Grey bars
indicate gaps in some of the aligned sequences.
A  phylogenetic  tree  of  the  MBD  amino  acid  sequences  of  all  eleven  polypeptides  was
computed using the ClustalW software at GenomeNet and is shown in Fig. 11.
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Fig. 11. Unrooted dendrogram depicting
methyl-CpG-binding  domains  of  the
human  protein  family.  A  tree
representation shows the similarity between
the human MBD proteins. The left branch
clusters  the  original  5  MBD  proteins.
Branch  lengths  are  proportional  to  the
amount of inferred evolutionary change.
Four major MBD subsets  are indicated in  Fig.  11.  The MBDs of the originally described
proteins (MBD1, MBD2, MBD3, MBD4, and MECP2) are found as one group besides a
second (BAZ2A/TIP5, BAZ2B) and a third subset (CLLL8/SETDB2 and SETDB1) which are
joined by a very short branch. KIAA1461/MBD5 and KIAA1887/MBD6 appear in a fourth
branch. MBDs of the original five proteins are more similar to each other than to the novel
ones,  which explains  why BLAST analyses with  the MBD of MECP2 as query failed to
identify the second, third, or fourth class.
3.1.3 Domain analysis
An analysis of the amino acid sequences revealed that the MBD was the only domain shared
by all eleven sequences. 
The MBD of MECP2, MBD1, MBD2, MBD4, and BAZ2A/TIP5 mediates binding to DNA,
in case of MECP2, MBD1, and MBD2 preferentially to methylated CpG (Ng  et al., 2000,
Strohner et al., 2001, Lewis et al., 1992, Hendrich and Bird, 1998,  Bird, 2002). MBD4 has a
special role acting as a DNA repair enzyme as described in the introduction.
In case of human MBD3 and SETDB1, the MBD has been shown to mediate protein-protein
interactions (Schultz et al., 2002, Saito and Ishikawa, 2002). Xenopus MBD3 is exceptional in
its binding to methylated CpGs which can be explained by the difference of an amino acid
residue within the MBD (Lys30) important for DNA binding (Saito and Ishikawa, 2002). It
remains  to  be  determined  whether  the  MBDs  of  BAZ2B,  CLLD8/SETDB2,
KIAA1461/MBD5,  and  KIAA1887/MBD6  mediate  DNA  binding  or  protein-protein
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interactions.
Additional domains found in seven of the eleven polypeptides indicate that they are associated
with  chromatin  and  function  in  epigenetic  mechanisms  of  gene  regulation.  Some  of  the
proteins are already known to be involved in transcriptional repression and the domains of the
remainder strongly suggest a comparable function.
MECP2 recruits  the Sin3A co-repressor complex and MBD2 the Mi-2/NuRD co-repressor
complex, which itself contains MBD3. Both complexes contain HDACs, and MBD1 is also
associated with HDAC activity although the identity of the deacetylase remains unknown (Ng
et al.,  2000). Within the C-terminal  part  of MECP2 a histidine and proline-rich region is
present which is conserved in certain neural-specific transcription factors (Vacca et al., 2001).
BAZ2A/TIP5 is part  of the nucleolar remodeling complex (NoRC) which represses rDNA
transcription by recruiting histone methyltransferases, HDACs, and DNA methyltransferases
(Santoro et al., 2002). 
BAZ2B has a domain structure similar to BAZ2A/TIP5. Both contain a DDT domain (DNA
binding homeobox and Different  Transcription factors)  and a tandem PHD-bromodomain.
The PHD domain is a C4HC3 zinc-finger-like motif and the bromodomain consists of 110
amino acids and is found in many chromatin-associated proteins that can interact specifically
with  acetylated  lysine.  Tandem  PHD-bromodomains  have  been  found  in  several
transcriptional co-repressors (Schultz et al., 2002). The DDT domain is exclusively associated
with nuclear domains in other proteins and was found in different transcription and chromatin
remodeling factors (Doerks  et al., 2001). An AT-hook motif (which allows binding to the
minor groove of AT-rich DNA regions) was found in BAZ2A/TIP5 but not in BAZ2B. 
SETDB1 is a H3-K9 histone methyltransferase (Schultz  et al., 2002). Its mouse homologue,
ESET,  has  furthermore  been shown to interact  with  the  mSin3A/B co-repressor  complex
(Yang  et  al.,  2002).  The  SET  domain  is  a  signature  motif  for  lysine-specific  histone
methyltransferases (Wang et al., 2001, Tachibana et al., 2001). This domain is also present in
CLLD8/SETDB2 to which no function has yet been assigned. A recent  study showed the
formation  of  an  S-phase-specific  complex  including  SETDB1,  MBD1,  and  CAF-1  that
facilitates methylation of H3-K9 during replication-coupled chromatin assembly (Sarraf and
Stancheva, 2004) .
The predicted protein sequence of KIAA1461/MBD5 harbors a PWWP motif (Stec  et al.,
1998) named after the conserved amino acids Pro-Trp-Trp-Pro. It was first described in the
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WHSC1 protein, encoded by a gene within the Wolf-Hirschhorn syndrome critical region. The
PWWP domain of Dnmt3b, a DNA methyltransferase, has recently been shown to bind to
DNA (Qiu et al., 2002). A common feature of PWWP containing proteins is the presence of
additional domains known to be associated with chromatin (Qiu  et al., 2002). Furthermore,
KIAA1461/MBD5 has been shown to interact with the KIAA1549 protein in a yeast-two-
hybrid experiment (http://www.kazusa.or.jp/huge/ppi). This interaction partner has not been
studied in detail so far, but contains a serine-rich stretch as well as a helix-turn-helix motif
(PS00622, LuxR family) according to Prosite. Helix-turn-helix motifs can be found in many
transcription regulation proteins. Interestingly, the KIAA1461/MBD5 gene lies in a region that
was found to be deleted in a mentally retarded patient (Koolen et al., 2004).
In the predicted protein sequence of KIAA1887/MBD6 only a proline-rich extension but no
protein motif as such could be found. 
The  co-existence  of  MBDs  and  domains  involved  in  histone  modification  (e.g.  the  SET
domain  and  the  bromodomain)  in  SETDB1,  SETDB2,  BAZ2A,  and  BAZ2B indicates  a
potential connection between the recognition of methylated DNA and histone modifications.
This link is especially tempting for SETDB1, which has been shown to methylate histones
(Schultz  et  al.,  2002),  while  its  mouse  homologue  ESET  binds  to  mSinA  co-repressor
complex (Yang et al., 2002) that is also bound by MECP2 (Nan et al., 1998).
3.1.4 MBD proteins in other species
In the mouse homologues were found for all human MBD proteins. Sequence identity scores
range from 63.8% to 94.0% (Tab. 22) indicating a conserved function in both species. Human
and mouse MBD1, MBD2, MBD3, MBD4 and MECP2 are curated orthologues (Hendrich
and Bird, 1998, Hendrich et al., 1999, Quaderi et al., 1994, D'Esposito et al., 1996).
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Human protein Mouse protein % identity
MECP2 MECP2 (541 aa) 93.4% in 542 aa
MBD1 MBD1 (713 aa) 66.8% in 698 aa
MBD2 MBD2 (454 aa) 93.2% in 545 aa
MBD3 MBD3 (362 aa) 85.1% in 355 aa
MBD4 MBD4 (631 aa) 63.8% in 647 aa
BAZ2A BAZ2A (1972 aa) 80.1% in 2039 aa
BAZ2B ENSMUSP00000028367 (2065 aa) 82.6% in 2027 aa
SETDB1 ESET (1457 aa) 91.0% in 1465 aa
SETDB2 ENSMUSP00000022552 (701 aa) 65.2% in 715 aa
MBD5 ENSMUSP00000036847 (1518 aa) 94.0% in 1521 aa
MBD6 ENSMUSP00000026476 (101 aa) 93.5% in 216 aa
Table 22. Mouse homologues to human MBD proteins.  Comparison of the human MBD proteins and their
mouse  homologues.  Identity  scores  were  calculated  with  the  LALIGN  program
(http://www.ch.embnet.org/software/LALIGN_form.html).  The  numbers  of  aa  residues  are  indicated.  a) The
number of aligned amino acids can exceed the residue number of the sequences due to gaps inserted by the
algorithm.
Homology searches in the Ensembl database revealed the following murine homologues of
BAZ2B,  CLLD8,  KIAA1461/MBD5 protein,  and  KIAA1887/MBD6 protein.  The  mouse
homologue  of  BAZ2B,  the  Ensembl  protein  ENSMUSP00000028367  (gene
ENSMUSG00000026987),  shows  a  82.6%  amino  acid  sequence  identity.  The  predicted
mouse gene ENSMUSG00000021980 coding for Ensembl protein ENSMUSP00000022552
has a 65.2% amino acid sequence identity to the human CLLD8/SETDB2. It was furthermore
found,  that  the  predicted  gene  ENSMUSG00000036792  coding  for  the  Ensembl  protein
ENSMUSP00000036847 is a mouse homologue of human KIAA1461/MBD5 protein with a
94.0% amino acid  sequence  identity.  For  the  KIAA1887/MBD6 protein,  the  mouse  gene
sequence ENSMUSG00000025409 (Ensembl protein ENSMUSP00000026476) with 93.5%
sequence identity was present in the database.  However, the latter database entry consists of
only 216 amino acids.
The  existence  of  corresponding  translated  proteins  remains  to  be  determined  for  all  four
mouse genes. 
DNA methylation as a mechanism of gene expression regulation exists also in plants. In the
database searches plant MBD proteins were detected as well.  The Pfam database contains
polypeptides from  Arabidopsis thaliana (thale cress) and  Triticum aestivum (bread wheat).
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BLAST analyses revealed additional proteins in  Zea Mays (maize),  Hordeum vulgare (two-
rowed barley) and Lycopersicon esculentum  (tomato). Entries for MBD containing proteins
from plants over C. elegans (nematode) to mouse and human are present in Pfam.
3.1.5 Expression patterns of MBD genes
Expression analyses had been carried out previously for all genes of the mouse/human MBD
family  except  for  KIAA1461/MBD5 and KIAA1887/MBD6 (only  the  abundance  of
KIAA1887/MBD6 ESTs in different tissues had been reported  (Nagase  et al., 2001a)). The
results of published Northern blot experiments are summarized in Tab. 22. Since expression
levels  of  MBD4 were too low to be detected by Northern blots,  only results  of  RT-PCR
studies  in  three  tissues  are  shown.  However the presence of  MBD4 EST sequences  from
numerous tissues points to a ubiquitous expression (Unigene).
Tissue MECP2a) MBD1b) MBD2b) MBD3b) MBD4b) BAZ2Ad) BAZ2Bd) SETDB1e) SETDB2c) MBD5f) MBD6g
)
Brain + + + + + + (+) + (+) (+) (+)
Heart + + + + + + + + + +
Kidney + + + + + - + + (+) +
Liver + (+) (+) + (+) - + + (+) +
Lung + + + + + - + + (+) (+)
Skeletal
muscle
+ + + + + + + (+) + +
Spleen + + + + - + + +
Testis + + + + + + + + +
ES cells - (+) + +
Placenta + + + + (+) + +
Pancreas + + + + + + +
Table 23. Expression patterns of the mouse/human MBD genes. The table shows the expression of the eleven
MBD genes in major tissues as detected by Northern blot. Empty spaces denote lacking information for that
tissue. (+) indicates very low or doubtful expression, - no expression.  a) (D'Esposito  et al., 1996, Coy  et al.,
1999).  b) (Hendrich and Bird, 1998) For these genes, comprehensive expression data was only available from
mouse.  c) (Mabuchi  et  al.,  2001)  Expression in  additional  tissues  has been reported.  d) (Jones  et  al.,  2000)
Expression  in  additional  tissues  has  been reported.  e) (Nomura  et  al.,  1994)  SETDB1 was originally called
KIAA0067. f) Northern blot results of this study. g) (Nagase et al., 2001a) and Northern blot results of this study.
Northern blot analyses for  KIAA1461/MBD5 and KIAA1887/MBD6 were performed during
63
3. Results
                                                                                                                                                                                                                                                           
this  thesis. Strong  signals,  representing  a  transcript  of  ~8  kb  were  detected  for
KIAA1461/MBD5 in  skeletal  muscle,  heart,  pancreas,  kidney and  placenta.  A faint  band
could be detected in brain, lung and liver. For KIAA1887/MBD6 a strong band corresponding
to a transcript  of ~5 kb was present in heart,  kidney, liver, skeletal  muscle, placenta, and
pancreas, and weaker signals could be seen for brain and lung tissue (Fig. 12).
Fig.  12.  Northern  blots  for
KIAA1461/MBD5 and
KIAA1887/MBD6.  Human  multiple
tissue  Northern  blot  showing  the
expression of the  KIAA1461/MBD5
and  KIAA1887/MBD6 genes.  The
calculated sizes of the transcripts are
~5 kb for  KIAA1887/MBD6 and ~8
kb  for  KIAA1461/MBD5, indicated
by  arrows.  A  β-actin  probe  was
hybridized as loading control, shown
at the bottom.
Taken together,  MBD1, MBD2, MBD3, and  MECP2 as well as  SETDB1, CLLL8/SETDB2,
BAZ2A, KIAA1461/MBD5, and KIAA1887/MBD6 show a broad tissue distribution. In contrast
the expression of  BAZ2B is  more restricted according to  Northern blot  results  (Table 23)
(Jones  et al., 2000). It is noteworthy, that  CLLL8/SETDB2, BAZ2A, KIAA1461/MBD5, and
KIAA1887/MBD6 are expressed at very low levels in brain.
3.2 Search for MECP2 paralogues
3.2.1 Objective
The function of MECP2 is not only dependent on the MBD, but also on other domains of the
protein and on its overall structure (Klose and Bird, 2004). As yet, only the 3D-structure of the
MBD has been resolved while the exact shape of the entire protein remains to be elucidated. 
A bioinformatics approach was therefore used to find human proteins with a global similarity
to MECP2. Such paralogue proteins are thought to arise through gene duplication and can
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give clues about the tertiary structure and about related functions of the protein of interest.
3.2.2 Proteins with an overall sequence similarity to MECP2
To avoid false positives in this search, MECP2 was first checked for repetitive sequences. A
dotplot analysis revealed three such regions with low sequence complexity (aa 20 - aa 90, aa
160 - aa 200, and aa 340 - aa 400, see also Fig. 13). These regions were masked and  BLASTP
searches against the NCBI protein sequence database were performed. 
Fig. 13. DotPlot output of a comparison of MECP2
to itself. Every dot in the graph represents a similarity.
Clusters of dots that do not lie on the diagonal indicate
potential  repetitive  sequences.  Such regions with low
complexity are indicated by LC.
The BLASTP searches were followed by database queries of the sequence similarity database
(SSDB) at GenomeNet and the BLink database at NCBI using the search terms hsa:4204 and
P51608 respectively.
The BLink search revealed a total of 30 matches in the Homo sapiens proteome, but due to
redundancy there were only 12 unique hits, four of which were MBD1, MBD2, MBD3 and
MBD4. Since similarities to the MBD protein family members were mainly due to consensus
in the MBD domains and therefore not of interest for overall structural similarity, they were
disregarded. The remaining eight proteins are summarized in Table 24. The SSDB query with
a  SW-score  cut-off  at  200  yielded  18  non-redundant  hits,  including  MBD1,  MBD2  and
MBD4.
The list resulting from the BLink search (8 proteins) and the SSDB query (15 proteins) was
compared to the 100 best hits of the protein Blast with the masked MEC2_HUMAN as query
sequence. Only one protein gave a positive result with all three search strategies.
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Gene symbol Protein name SSDB BLink Blast
NEFH Neurofilament heavy polypeptide x x x
MLLT2/AF4 MLL/AF1p fusion - Myeloid/lymphoid or mixed-lineage leukemia 
(trithorax homolog, Drosophila)
x x
FOXG1B Forkhead box G1B, Oncogene QIN x
TRDN Triadin x
PRG4 Proteoglycan x
SRRM1 Serine/arginine repetitive matrix 1 x
SRRM2 Serine/arginine repetitive matrix 2 x
MDC1 Mediator of DNA damage checkpoint 1, KIAA0170 gene product x
NOLC1 Nucleolar and coiled-body phosphoprotein 1 x
BAT2 HLA-B associated transcript 2 x
IRS2 Insulin receptor substrate 2 x
SRCAP Snf2-related CBP activator protein x
CRK7 CDC2 related protein kinase 7 x
AIM1 Absent in melanoma 1 x
Hypothetical protein BC001584 x
ANK2 Ankyrin 2, neuronal x
ZNF469 Zinc finger protein 469 x
Table 24. Results of the database queries. Crosses indicate positive results in the searches. SSDB = Sequence
similarity database, BLink = Blast Link database, Blast = Blast search with masked MEC2_HUMAN as query.
Only NEFH could be found in all 3 search methods.
The human neurofilament NEFH (Mattei  et al., 1988) belongs to the intermediate filament
family and has been associated with amyotrophic lateral sclerosis (ALS). Overexpression of
Nefh causes motor neuron degeneration in transgenic mice (Collard et al., 1995) and deletions
in  the  C-terminal  part  of  NEFH can  be  found  in  ALS patients  (Figlewicz  et  al.,  1994),
supporting the link between NEFH and ALS. The alignment with MECP2 shows a similarity
in the C-terminal part of NEFH as depicted in Fig. 14 and Annex 6.1.
Fig. 14. Alignment of MECP2 (486 aa) and NEFH (1020 aa) derived form the SSDB. The overlap of 494 aa
includes gaps and has an overall similarity of 0.235 (with 1 being a perfect similarity). Rather than having an
overlap in only one domain, the whole MECP2 protein has a similarity to the C-terminal part of NEFH.
The product of the MLLT2 gene, also called AF4 for "ALL1-fused gene from chromosome 4"
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is  a  serine-  and  proline-rich  putative  transcription  factor  with  a  glutamine-rich  carboxy
terminus that results from translocation of ALL1 in acute leukemias. Fig. 15 represents an
alignment of MLLT2 and MECP2.
Fig. 15. Alignment of MECP2 (486 aa) and MLLT2 (2311 aa) derived from the SSDB. The overlap of 528
aa includes gaps and has an overall similarity of 0.225 (with 1 being a perfect similarity).
FOXG1B was described as the QIN gene product and is a transcription factor with a forkhead
domain (Li and Vogt, 1993). It controls the fate of Cajal-Retzius cells  (Hanashima  et al.,
2004).
Triadin  (TRDN) is  a  protein  thought  to  be  involved  in  the  calcium release  from muscle
contraction (Brandt et al., 1993). It is also the founder of the poorly understood triadin protein
family (for review see Marty, 2004). Proteoglycan 4 (PRG4) also known as SZP and CACP
can  act  as  megakaryocyte-stimulating  factor  (Merberg  et  al.,  1993).  It  is  expressed  by
chondrocytes in bovine articular cartilage (Schumacher et al., 1994).  PRG4 is thought to be
the disease gene for  camptodactyly-arthropathy-coxavara-pericarditis  (CACP) syndrome and
has an isoform known as HAPO for hemangiopoietin. Finally, it is a growth factor acting on
hematopoietic and endothelial progenitor cells (Liu et al., 2004). 
SRRM1 is a co-activator of pre-mRNA splicing. It binds different splicing factors, associates
with the nuclear matrix, and is involved in mRNA export (Wagner et al., 2003).  SRRM2 is
also involved in splicing, but was shown to be less important than SRRM1 for this process in
vitro (Blencowe et al., 2000).
MDC1, also termed NFDB1, works with H2AX to promote the recruitment of repair proteins
to DNA breaks and it controls damage-induced cell-cycle arrest checkpoints (Stewart  et al.,
2003). 
NOLC1, formerly known as p130 or Nopp140, is a putative snoRNP assembly factor (Yang et
al., 2000).
Little is known about BAT2, but Lehner et al. in 2004 proposed a role in the regulation of pre-
mRNA splicing.
IRS2 links cell surface receptors to the intracellular insulin/IGF signaling cascade and has an
important  role  in  both  peripheral  insulin  response  and  pancreatic  beta-cell  growth  and
67
3. Results
                                                                                                                                                                                                                                                           
function.  Dysregulation  of  Irs2  signaling  in  mice  causes  the  failure  of  compensatory
hyperinsulinemia during peripheral insulin resistance (for a review see Lee and White, 2004).
In humans it  has been associated with type II diabetes (Mammarella  et  al.,  2000),  severe
obesity, and glucose intolerance (Lautier et al., 2003) .
SRCAP  is  an  ATPase  binding  to  the  CREB-binding  protein  (CBP)  and  a  transcription
activator  (Johnston  et  al.,  1999).  Furthermore,  it  is  also  a  co-activator  for  the  androgen
receptor  and  can  enhance  glucocorticoid  receptor-mediated  transcription  (Monroy  et  al.,
2003).
CRK7, also termed CrkRS, is a protein kinase found in nuclear SC35 speckles (Ko  et al.,
2001).
A single-nucleotide polymorphism (SNP) in  AIM1 has been associated with differences in
skin color in humans (Fukamachi et al., 2001).
ANK2 is  a  spectrin-binding  protein  that  is  required  for  localization  of  inositol  1,4,5-
trisphosphate  receptor  and  ryanodine  receptor  in  neonatal  cardiomyocytes  (Mohler  et  al.,
2004).  It  was  furthermore  linked  to  long  QT  syndrome  4  (sick  sinus  syndrome  with
bradycardia) (Mohler et al., 2004).
ZNF469  is  a  zinc  finger  protein  that  was  first  described  as  the  KIAA1858 gene  product
(Nagase et al., 2001b). 
None of the proteins could be found in the protein structure database PDB, which means that
their  3D structure has not been determined as yet.  Sequence comparison of MECP2 with
proteins for which structural data is available, could have helped to get an idea of the 3D
structure of MECP2 itself.
3.3 MECP2 target genes
3.3.1 Objective
Even though MECP2 has been identified as disease gene for Rett syndrome in 1999 (Amir et
al., 1999), the disease is still poorly understood. Especially knowledge on the exact function
of MECP2, i.e. the genes regulated by MECP2 as a transcriptional repressor is missing. In
addition, it is unknown whether MECP2 has functions other than transcriptional regulation.
A mouse model created by the Bird group (Guy et al., 2001) was used to find genes regulated
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by MECP2 in the brain. The approach consisted of a microarray hybridization of total brain
RNA from a Mecp2-/y mouse versus total brain RNA from a healthy litter mate control. The
hybridization  results  were verified  by northern blot  and real-time PCR performed by our
collaborators in Edinburgh. Subsequently, chromatin immunoprecipitation was carried out to
prove direct binding of MECP2 to the genomic region of genes that might be involved in the
disease.
Four microarray studies on Rett syndrome have been published since the start of this thesis.
Two  studies  used  cultured  cells,  i.e.  primary  fibroblasts  (Traynor  et  al.,  2002)  and
lymphoblastoid cells (Ballestar  et al., 2005). Colantuoni and colleagues isolated RNA from
post mortem human brain tissue (Colantuoni et al., 2001) and Tudor and colleagues isolated
RNA from whole brains of MECP2 mutant mice (Tudor et al., 2002).
Apart  from  the  study  by  Tudor  and  colleagues,  the  biological  material  used  in  these
experiments does not seem to be well suited to find the neuronal target genes of MECP2
responsible  for  the  phenotype  (see  4.3.6  DNA  microarray  studies  and  chromatin
immunoprecipitation).
3.3.2 Genes differentially expressed in Mecp2-null mice – a microarray study
Gene expression levels in the brains of a symptomatic Mecp2-/y mouse were compared to the
expression levels of a wt litter mate control brain. Isolated RNA was sent by our collaborators
from  Edinburgh.  The  RNA  was  fluorescently  labeled  with  Cy3  and  Cy5  in  a  reverse
transcription reaction and co-hybridized to a microarray with 13,627 cDNA clones. 
After scanning, image analysis and quality control the data was subjected to ANOVA. From
the resulting clones, those with an intensity ratio of 2.00 or higher were considered relevant. A
total of 17 clones were found to be either up- or down-regulated at least 2-fold in the brain
RNA of the mutant mouse. Due to redundancy, the 17 clones correspond to 11 transcripts of
which three were down- and eight were up-regulated (Table 25).
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Fold 





3.4412 + Sgk1 Serum/glucocorticoid regulated kinase Mm.28405 AA273540
3.2992 + Sgk1 Serum/glucocorticoid regulated kinase Mm.28405 AI527833
2.6313 + Fkbp5 FK506 binding protein 5 (51 kDa) Mm.276405 BC015260
2.5815 + Fkbp5 FK506 binding protein 5 (51 kDa) Mm.276405 BC015260
2.3051 + Fkbp5 FK506 binding protein 5 (51 kDa) Mm.276405 BC015260
2.4131 + Cirbp Cold inducible RNA binding protein Mm.17898 NM_007705 
2.254 + Cirbp Cold inducible RNA binding protein Mm.17898 NM_007705 
2.1947 + Cirbp Cold inducible RNA binding protein Mm.17898 NM_007705 
2.2748 + Sult1a1 Sulfotransferase family 1A, phenol-preferring, member 1 Mm.17339 AB029487
2.2651 - Sorcin Mm.96211 AK008970
2.2386 - Hsp105 Heat shock protein, 105 kDa Mm.270681 AA105012
2.0727 - Hsp105 Heat shock protein, 105 kDa Mm.270681 BC018378
2.2012 + Pomc1 Pro-opiomelanocortin-alpha Mm.277996 BC061215
2.1584 + Scya17 Small inducible cytokine subfamily A17 Mm.41988 NM_011332
2.1477 - Gja12-pending Gap junction membrane channel protein alpha 12 Mm.40016 AW742272
2.1375 + S3-12-pending Plasma membrane associated protein, S3-12 Mm.347924 NM_020568
2.0019 + RIKEN cDNA 4930546H06 gene Mm.227456 AK016052 
Table 25. Gene expression changes in the brain of an Mecp2-/y animal compared to a wt litter mate control
detected by microarray hybridizations. Transcripts with more than 2-fold expression difference are shown.
Some genes are represented by more than one differential clone on the array and therefore listed several times.
The identity of all 17 clones was confirmed by sequencing of the spotted DNA. Up-regulation (+) and down-
regulation (-) in the Mecp2-/y sample are indicated.
At least 5 of the 11 differentially expressed genes (Fkbp5, Sgk, Pomc, Sult1A1, and Hsp105)
are known to be regulated by the stress hormones, glucocorticoids. Stress provokes release of
corticotropin-releasing hormone (CRH) by the hypothalamus, which stimulates synthesis of
adrenocorticotropic hormone (ACTH). ACTH in turn causes the adrenal cortex to produce
circulating  glucocorticoids  (cortisol  in  humans,  corticosterone  in  rodents)  which  bind  to
glucocorticoid receptors and coordinate the transcriptional response (Reichardt and Schütz,
1998). Negative feedback by glucocorticoids on the hypothalamus and pituitary ensures that
the stress response is transient under normal conditions. 
The POMC polypeptide is the precursor of ACTH. The POMC gene was found to be higher
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expressed in the brain of the Mecp2-/y mouse as compared to the brain of its wt litter mate. Sgk
and Sult1A1 are reportedly induced by glucocorticoids (Lang and Cohen, 2001, Duanmu et al.,
2001) and they were found to be up-regulated in the brain of the Mecp2-/y animal. Another up-
regulated glucocorticoid-inducible gene, Fkbp5, encodes a peptidyl-prolyl cis-trans-isomerase
associated with glucocorticoid receptor complexes (Yoshida et al., 2002). Hsp105, also called
Hsp110,  was down-regulated in the brain of the  Mecp2-deficient  animals (Fig.  29 A).  Its
expression is inhibited by the glucocorticoid dexamethasone (Wadekar et al., 2001). Cirp (the
cold-inducible  RNA binding protein gene)  is  induced by low temperature  or  low oxygen
tension (Wellmann et al., 2004) but is not known to be induced by glucocorticoids. 
3.3.3 Localization of MECP2, FKBP5, and SGK in mouse brain
Next,  the immunolocalization of FKBP5, SGK (=SGK1) and MECP2 proteins in  selected
brain regions  of  adult  female  mice  were examined.  The results  revealed  a significant  co-
localization of FKBP5 with cells that also synthesize MECP2 (Fig. 16 A, B). A few MECP2-
positive cells showed low or indetectable levels of FKBP5 staining (e.g. cortical cells in the
position of Cajal-Retzius cells;  Fig. 16 A). Many cells positive for  SGK and  MECP2 were
found, though fewer than positive for  FKBP5 and  MECP2 (Fig. 16 C-E). In addition, cells
producing either MECP2 or SGK are present in the brain (Fig. 16 D, E). As these animals had
not been stressed or glucocorticoid-treated,  the data suggest that presence of MECP2 in a
neuronal cell is compatible with FKBP5 and SGK synthesis as proposed in Fig. 16. Therefore,
MECP2 does not act as a transcriptional silencer on Fkbp5 of Sgk in the brain.
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Fig.  16.  Expression  of  MECP2,  FKBP5,  and  SGK  (=SGK1)  in  the  brain  of  adult  female  mice.
Immunolocalization of MECP2 (green signals, FITC-coupled secondary antibody), FKBP5 (red signals in A and
B, Cy3-coupled secondary antibody), and SGK (red signals in C-E, Cy3-coupled secondary antibody) on cryostat
sections of mouse brain. Panels show the temporal cortex (A), the cerebellum (B, D), the region immediately
above the corpus callosum (C), and the lateral ventricle (E). Blue signals: DAPI-stained nuclei. Gl: granular cell
layer.  Ml:  molecular  cell  layer.  A clear  cellular  overlap  of  the  staining with anti-MECP2 and  anti-FKBP5
antibodies can be seen for the majority of cells in all brain regions. There are few MECP2-positive cells with an
absent or weak FKBP5 expression: the most superficial cortical layer is FKBP5-negative (arrows in A) and some
cells with weak FKBP5 signals can be seen in the molecular and granular cell layer of the cerebellum. Many cells
co-express MECP2 and SGK in the brain, for example cells above the corpus callosum (C) and cells in the
granular cell layer of the cerebellum (D). Distinct MECP2-positive cells in the molecular layer show only a weak
homogeneous staining with the SGK antibody (D). The strongest SGK signals were detected in cells lining the
ventricles (top cell layer in E). These cells show absent or very weak MECP2-staining in contrast to cells at the
subluminal site.  Scale bars in A equal 100 μm, in B, C, D 50 μm, and in E 25 μm. 
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3.3.4 Establishment of chromatin immunoprecipitation (ChIP)
To  test  the  direct  interaction  of  MECP2  and  Fkbp5,  the  chromatin  immunoprecipitation
method was established and applied in this work. ChIP is the technique of choice to study the
in vivo binding of DNA-associated proteins. 
Even though laborious optimization of many parameters is required to obtain proper results
with ChIP (for a review, see Das et al., 2004), the technique has been widely used in recent
years. Among the conditions that have to be adjusted are the time and intensity of fixation, the
purification of  the input  material  (i.e.  purification of  cells,  or  even isolation of  nuclei  or
chromatin) the shearing of the chromatin, the washing of the immunoprecipitated complexes,
and the final detection. 
For the experiments carried out in this thesis, fixation with 1% formaldehyde in the medium
for 10 minutes at 37°C proved to be the most efficient way to bind the proteins of interest to
the DNA. Using these settings, the MECP2 polypeptide was properly coupled to the DNA
while  most  of  the epitopes  recognized by the  polyclonal  anti-MECP2 antibody were still
accessible. Differences between batches of anti-MECP2 antibodies were however observed.
Chromatin immunoprecipitation with antibodies for histones was generally more reliable and
resulted in  more  precipitated  DNA.  This  is  probably due to  the  higher  abundance of  the
histone proteins as compared to MECP2 or GR in the chromatin regions studied.
The shearing parameters for the fragmentation of the chromatin had to be optimized for the
two types of biological material used (primary neurons and grounded brain tissue). Different
sonication times and intensities were tested, using a Branson sonifier. Optimal results were
achieved with 5 pulses of 30 seconds at 100 % duty and output level 5. The sonication was
carried out in 2 ml buffer containing sodium dodecyl sulfate (SDS). The samples were kept in
ice cold salt water to prevent the disruption of the DNA-protein complexes by heat as well as
to hinder the formation of foam during the shearing procedure.
The described settings resulted in a smear of DNA ranging from 200 bp to about 1000 bp.
These fragment sizes allowed a proper amplification after immunoprecipitation and isolation
of the DNA. 
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Fig. 17. DNA fragment distribution obtained by sonication of
chromatin. (A)  Lanes  1  to  4  depict  the  smears  obtained  by
sonication with 2, 3, 4 and 5 pulses of 30 sec at output level 5,
respectively. Line 4  represents  the  optimal  DNA fragment size
distribution for amplification with specific primers after ChIP. (B)
DNA smear resulting from sonication (5 pulses of 30 sec, output
level 5) of chromatin from brain tissue. Arrowheads indicate the
pUC mix marker band at 501 bp.
3.3.5 MECP2 binding sites in the genomic regions of Fkbp5
Since the only DNA motif necessary for MECP2 binding is the dinucleotide m5CpG (Nan et
al., 1993), it is not trivial to predict binding sites from the genomic sequence alone. Therefore,
a comparative genomics approach was used to find genomic fragments conserved between the
mouse Fkbp5 and the human FKBP5 (see methods section 2.2.1.1). This data was compared
to binding sites of known transcription factors which were mapped to the  Fkbp5 genomic
region. To do so, all motifs of the Transfac database were blasted against the Fkbp5 region of
in the mouse genome. Finally, the CpG content of the sequence was considered, since CpG
islands are often found in promoters of genes, but are usually unmethylated and hence not a
promising binding region for MECP2. Primer pairs were designed covering regions of about
1 kb at the two most promising target sites (region 1 with primer pairs 1_0 to 1_4 and region 2
with primer pairs 2_1 to 2_4, see Fig. 18).
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Fig.  18.  Comparison  of  human  FKBP5 and  mouse  Fkbp5 genomic  regions. Ensembl  representation  of
sections of human chromosome 6 and mouse chromosome 17 depicts the known transcripts, 5' to 3', right to left.
Eponine denotes regions predicted to contain transcription start sites and promoters. The % GC curves show the
percentage of GC base pairs in the sequence. Arrows indicate the regions covered with primers to find MECP2
binding sites. The black circle depicts the human exon 1 that was missing in the mouse transcript.
In the Ensembl database (release 24.33.1) the mouse Fkbp5 transcript was missing the first
exon present in the human transcript (Fig. 18). Thus, an RT-PCR experiment was performed
with  one  primer  corresponding  to  a  sequence  in  the  fourth  exon  and  the  other  primer
corresponding to a sequence in the first and second exon of the predicted transcript. The size
of the PCR band confirmed the existence of a mouse transcript that contains an exon (similar
to the first exon of  FKBP5 in the human genome) upstream of the transcription start in the
Ensembl database (Fig. 19).
Fig. 19. PCR using mouse brain cDNA with primers specific for mouse Fkbp5. The
first  exon  of  Fkbp5 is  not  part  of  the  Ensembl  known  transcript
(ENSMUST00000062167), but was present as EST in the database. RT-PCR revealed a
cDNA fragment that corresponds to a sequence from exon 1 to exon 4 in brain tissue.




                                                                                                                                                                                                                                                           
To confirm the binding of MECP2 to the two regions 1 and 2 of Fkbp5, ChIP was performed
with  whole  mouse  brain  tissue  (Fig.  20).  Specific  interactions  could  be  detected  in  both
regions in wt brains. As a negative control,  Mecp2-null mouse brain tissue was used. In this
case, no PCR products were obtained. This argues for the specificity of the antibody and
against  a cross-reaction with a protein other than MECP2. An antibody against  acetylated
histone H3 was used as positive control.
Fig. 20. Chromatin immunoprecipitation shows binding of MECP2 to the genomic region of Fkbp5. ChIP
with antibodies against MECP2 and acetylated histone H3 using total brain tissue. MECP2 binds to region 1_4
and region 2 (2_2 and 2_4) of the  Fkbp5 gene in  wt brain. Arrowhead: 242 bp DNA marker. SR1 negative
control: no template was used in the SR1 PCR reaction. Water control: H2O instead of template was used in the
PCR with specific primers.
Reliable binding of MECP2 to the Fkbp5 genomic regions 1_4, 2_2, and 2_4 could be shown
in  this  thesis,  as  well  as  to  the  regions  fkp  and  fkp1  detected  by  our  collaborators  in
Edinburgh. The relative position of the primers can be seen in  Fig. 21. The regions 1_4, 2_1
and 2_2 are poor in CpG content while the regions fkp1 and 2_4 contain many CpGs (Fig.
21). 1_4 and fkp1 flank a CpG island.
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Fig.  21.  Schematic  representation  of  the  mouse  Fkbp5 gene. Positions  of  primer  pairs  used  for  the
amplification of MECP2 antibody precipitated Fkbp5 genomic DNA fragments are indicated by black horizontal
bars. The positions of CpGs present in the region are visualized by vertical bars.
MECP2 only binds to methylated DNA. To determine whether the potential binding sites of
MECP2 determined by ChIP are methylated, bisulfite sequencing was performed. Genomic
DNA from wt mouse brain was treated with sodium bisulfite, amplified with primers specific
for  the  genomic  regions  1_4,  2_1,  2_2,  and  2_4 after  bisulfite  conversion,  cloned into  a
vector,  and  sequenced.  Since  sodium bisulfite  deaminates  unmethylated cytosine  residues
which results in an uracil residue, only m5C still produced a cytidine in the sequencing output.
The CpGs in the regions studied were mainly methylated, supporting the idea that these are
binding sites of MECP2 (Fig. 22).
Fig. 22.  Methylation status of CpGs in Fkbp5 genomic
DNA  determined  by  bisulfite  sequencing. The  four
genomic regions, 1_4 and 2_1, 2_2 (=  fkp), and 2_4 were
analyzed. DNA was derived from the brain of a  wt mouse.
For  each  region,  10  clones  were  sequenced.  Numbers
correspond  to  the  location  on  Ensembl  mouse  genome
chromosome  17  (release  24.33.1)  Methylated  CpGs  are
depicted by filled circles; unmethylated CpGs by open ones.
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3.3.6 MECP2 and the glucocorticoid receptor compete for binding to the GRE_2 locus
In response to glucocorticoids, the glucocorticoid receptor has been shown to bind to human
FKBP5 and induce its expression (U et al., 2004). So far, no studies on GR binding sites in
the mouse Fkbp5 genomic region were done.
Human and mouse  Fkbp5 genomic sequences were compared to identify the region in the
mouse genome corresponding to the GR binding site in the human genome. Such a region,
however, could not be detected in the mouse  Fkbp5 gene. Therefore, the Transfac database
was used to search for all regions in the Fkbp5 gene that show similarities to the GR binding
site consensus sequence stored in the database. Six such loci, called glucocorticoid response
elements (GRE), could be identified in this thesis (Fig. 23). 
Fig. 23. Fkbp5 intron/exon structure and the localization of GR response elements. Two Ensembl transcripts
(starting at  the two promoters,  respectively) are represented by black squares (exons),  5'  to 3',  right  to left.
Eponine denotes regions predicted to contain transcription start sites and promoters. The % GC curves shows the
percentage of GC base pairs in the sequence. Glucocorticoid receptor binding sites are indicated as blast hits and
the binding site common to GR and MECP2 (GRE_2) is marked by a grey arrow. 
In  order  to  test  whether  MECP2  binds  to  the  same  genomic  regions  as  GR,  chromatin
immunoprecipitation experiments were performed with antibodies against MECP2 and GR.
Primary  neurons  were  treated  with  an  synthetic  glucocorticoid  (dexamethasone),  with  a




                                                                                                                                                                                                                                                           
Fig.  24.  MECP2  and  GR  both  bind  to  the
GRE_2  genomic  region.  Chromatin
immunoprecipitation  results  reveal  MECP2
binding  to  the  GRE_2  region  under  normal
conditions (Ethanol) and in the presence of both,
RU-486  (RU)  and  dexamethasone  (Dex).  In
contrast,  GR  only  binds  when  ethanol  or
dexamethasone are present, but not if RU-486 is  
added to the medium. Reactions without antibody 
(No Ab) served as negative controls and genomic 
DNA as positive control.
Fig. 24 illustrates, that under normal conditions MECP2 and GR bind to the GRE_2 region.
MECP2 binding is abolished in the presence of the glucocorticoid dexamethasone. In contrast,
GR binding can be reversed by addition of RU-486 which restores MECP2 binding. These
results suggest a model in which MECP2 and GR compete for binding to the GRE_2 region
and the repressor function of MECP2 is fine-tuned by glucocorticoids. Addition of RU-486
alone led to dissociation of MECP2 as well as GR from the GRE_2 region. This suggests, that
excessive amounts of RU-486 disturb the gene expression regulation of Fkbp5 in that neither
the repressor MECP2 nor the activator GR binds to GRE_2 under this condition.
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4. Discussion
4.1 MBD protein family
4.1.1 Expression of new MBD protein family members 
For many years, MECP2 was thought to be a global transcriptional repressor. This assumption
was based on MECP2 expression in almost all tissues studied (D'Esposito et al., 1996, Coy et
al., 1999) and the fact that MECP2 is essential for embryonic development in mice (Tate et
al., 1996). However, mutations in MECP2 lead to Rett syndrome with an exclusively neuronal
phenotype.  This could be explained by a greater need of long lived, non-dividing neuronal
cells for a special chromatin state that involves MECP2 and tightly suppresses transcription of
genes not needed in that tissue. Another explanation would be that the loss of function of
MECP2 in non-neural tissues is compensated by another protein with similar properties.
In  this  study,  six  proteins  (BAZ2A,  BAZ2B,  KIAA1461/MBD5,  KIAA1887/MBD6,
SETDB1,  and  SETDB2)  with  a  methyl-CpG-binding  domain  in  mouse  and  man  were
identified as new members of the MBD protein family. Transcripts of  SETDB1, SETDB2,
BAZ2A, KIAA1461/MBD5, and  KIAA1887/MBD6 are  found  in  all  adult  tissues  studied.
SETDB2, BAZ2B, and KIAA1461/MBD5 show a low expression in brain and the mRNA levels
of KIAA1887/MBD6 are particularly lower than in other tissues. According to RT-PCR data
from  the  HUGE  database,  KIAA1461/MBD5 expression  is  basically  confined  to  the
cerebellum and the corpus callosum. The exact cell types that express BAZ2A/TIP5, SETDB1,
and SETDB2 as well as KIAA1461/MBD5 and KIAA1887/MBD6 in the brain are not known.
MECP2  is  found preferentially  in  mature  neurons  of  the  brain  (Shahbazian  et  al.,  2002,
LaSalle  et  al.,  2001). Should  one  of  the  other  MBD proteins  compensate  for  the loss  of
function of MECP2 in Rett syndrome it would be expected that the compensating gene shows
an expression pattern complementary to that of MECP2, in particular in peripheral tissues that
are  not  obviously  affected  in  the  disease.  More  detailed  studies  will  be  needed  on  the
expression patterns of the MBD protein family members to confirm this hypothesis.
Based on gene expression studies with Mecp2 knockout mice and on biochemical evidence, it
has  been  suggested  that  the  essential  function  of  MECP2  in  the  brain  might  not  be
transcriptional  regulation (Tudor  et  al.,  2002).  In view of  this  aspect  and of  the protein–
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protein  interaction  property  of  the  methyl-CpG-binding  domain  of  human  MBD3  and
SETDB1, functional compensation would not necessarily require a DNA binding capacity.
Except  for  KIAA1887/MBD6  all  presented  polypeptides  are  known  or  predicted  to  be
involved in mechanisms of gene expression regulation. In order to understand the higher-order
interplay of  MBD proteins  and  associated complexes,  it  will  be  a  major  task  to  identify
interacting proteins as well as regulated targets. This will help to solve the question whether
some of these proteins can functionally complement MECP2 in tissues other than the brain.
4.1.2 The MBD domain of the new family members
The sequence comparison of the MBD domains of all MBD proteins showed only few amino
acids conserved in all proteins. This raises the question whether the newly identified MBD
sequences do really bind m5CpGs.
Fig.  25.  Solution  structure  of
the MBDs of MBD1 (left) and
MECP2  (right).  The  α-helix
(yellow)  opposite  the  three  β-
sheets  (arrows  in  green  and
blue), that form the 3D structure,
can be seen. Loop 2,  important
for DNA binding, is turquoise in
the  MECP2  and  green  in  the
MBD1  structure.  (Images
adopted from PDB)
The solution structures  of the methyl-CpG binding domains  of three of the human MBD
proteins, namely of MECP2 (Wakefield et al., 1999), MBD1 (Ohki et al., 2001), and MBD4
(Wu et al., 2003) have been published. A 3-D model of the MBDs of MECP2 and MBD1 are
shown in Fig. 25. The structural data in these publications revealed residues important for
DNA binding.
The following amino acids and structures have been found to be important for DNA and more
specifically for m5CpG binding of MECP2: Loop 2 is inserted in the major groove of the DNA
while  the  α-helix  interacts  with the  sugar-phosphate  backbone.  The  methyl groups of  the
cytosines on the forward strand interact with hydrophobic side chains of Val-18, Tyr-32, and
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Arg-20. The residues Arg-42 and Ser-43 interact with the methyl groups on reverse strand.
Arg-20 and Arg-42 form hydrogen bonds with the guanines of the m5CpG dinucleotides.
Amino acid Residue present in
Val-18 MBD1, MBD2, and MBD3
Arg-20 MECP2, MBD1, MBD2, MBD3, MBD4, SETDB1, and BAZ2B
Tyr-32 MECP2, MBD1, MBD2, and MBD4
Arg-42 All MBD proteins except for MBD5, and MBD6
Ser-43 MECP2, MBD1, MBD2, MBD3, MBD4, and MBD6
Table 26. The existence of amino acids important for m5CpG binding in MBD1 in other MBD protein
family members. This summary shows that in the new MBD protein family members many of the residues are
not conserved. Also, in MBD4 and MECP2 Val-18 is not present. 
Important residues of the structure of MECP2 are summarized in Table 27. In contrast to the
methyl-CpG binding domain of MBD1 where Val-18, Arg-20, Tyr-32, Arg-42, and Ser-43 are
necessary for m5CpG binding, in MECP2 also Ile-35 interacts with a methylated cytosine. This
amino acid only exists in MECP2 and MBD4. Such structural differences probably cause the
different binding specificities of the MBD proteins (see 1. Introduction).
The  unrooted tree  in  Fig.  11 (Results 3.1.2)  shows that  the  MBD domain  of  MECP2 is
structurally most closely related to MBD4. However, MBD4 has a specificity for m5CpG/GpT
mismatches. This suggests, that either other domains present in the protein modify the binding
specificity of the MBD domain or that minor changes in the MBD can lead to an altered
binding behavior. Fig. 9 (Results 3.1.2) clearly shows that the methyl-CpG binding domains
of  all  MBD  proteins  vary  considerably  in  their  polypeptide  sequence.  It  is  even  more
intriguing, that at least three of the proteins (MECP2, MBD1, and MBD2) specifically bind
the very small m5CpG motif. This suggests, that even a great variation in the sequence of the
different MBDs still allows the same specialized m5CpG binding function
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Tyr-33 Interaction with methylated C
Ile-35 Interaction with methylated C
Table 27. Residues of the MBD of MECP2 and their function. Amino acids of the hydrophobic core form the
three β-sheets and the α-helix.
From the sequence alone it is not possible to predict whether the new MBD protein family
members will bind m5CpG or not. As far as the conservation of important residues in the
Tables 26 and 27 are concerned, a binding is not very likely since many of the amino acids
important for m5CpG-binding of MBD1 are not conserved. To get certainty about the binding
capabilities, DNA binding assays with the individual domain sequences will have to be carried
out. Since the MBDs of MBD3 and SETDB1 have been shown to bind to other polypeptides,
protein-protein interactions should also be studied (e.g. by yeast-two-hybrid screens).
This of course raises the question, whether the newly identified MBD proteins merit the name
MBD.  However,  it  is  nowadays  common  to  name  proteins  according  to  protein  family
members they show similarity to. A recent example are the proteins MBD3L1 and MBD3L2
that have homologies with MBD3 but do not even contain an MBD motif (Jiang et al., 2002).
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4.2 Search for MECP2 paralogues
A total  of  17  proteins  with  an  overall  sequence  similarity  to  MECP2 were  found in  the
different searches applied. Only two proteins were detected in the SSDB as well as the BLink
search,  namely  "myeloid/lymphoid  or  mixed-lineage  leukemia  (thrithorax  homolog,
Drosophila); translocated to, 2" (MLLT2) and "neurofilament, heavy polypeptide 200kDA"
(NEFH). NEFH was detected in all three analyses.
Proteins that were found in the database queries but  not in the BLAST search have their
similarity probably due to regions of MECP2 with low complexity such as the histidine-rich
region from aa 266 to aa 372 or the proline-rich region from aa 376 to aa 405 (Fig. 26).
Polypeptides similar to each other only due to matches in these domains are not likely to be
paralogues since such local resemblances will have arisen independently during evolution of
the proteins and are not remains of the sequence of a common ancestor. Therefore only NEFH
and MLLT2 were considered to have an overall  sequence similarity to MECP2 since they
were found in two database searches and NEFH is the most promising candidate as it was also
detected in the BLAST search in which the low complexity regions were masked.
Fig. 26. Graphical representation of MECP2 with the low complexity regions depicted in blue. The MBD is
shown in white, while the AT-hook motifs are indicated as turquoise ovals. The low complexity region next to
the C-terminal AT-hook corresponds to the histidine-rich region, while the low complexity region further to the
right is the proline-rich region in MECP2.
4.2.1 NEFH
NEFH is a member of the neurofilament protein family and is as such composed of a highly
conserved  alpha-helical  core  region  of  approximately  310  amino  acids  that  form double
stranded coiled-coils flanked by head (amino)- and tail (carboxy)-domains (Fig. 27).
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Fig. 27. Structure of the NEFH protein.. The C-terminal tail domain has sequence similarities to MECP2.
NEFH coassembles with "neurofilament, light polypeptide 68kDa" (NEFL) via its core region 
in vivo to form heteropolymers while it binds to neighboring filaments via the tail domain.
The amino acid sequence lysine-serine-proline (KSP) is repeated 51 times in the central part
of the tail domain. This aa triplet represents a major protein kinase recognition site (Julien et
al.,  1998).  This  explains  the  high  degree of  phosphorylation  of  the  protein  and  its  large
apparent Mr of 200 kDa, as determined by SDS-polyacryl amide gel electrophoresis (Liem et
al., 1978). 
The tail region in particular has similarities to MECP2. The complete sequence alignment
(Annex 6.1) shows a consensus for three KSP motifs between NEFH and MECP2, while the
poly-histidine and poly-proline segments present in MECP2 do not occur in NEFH. Also the
MBD  domain  of  MECP2  at  position  90-165  has  few  matching  aa  and  two  large  gaps.
Therefore,  the  KSP  phosphorylation  sites  are  the  only motifs  present  in  both  sequences.
Interestingly, the exact phosphorylation site of MECP2 as well as the kinase that adds the
phosphate  groups  remain  unknown.  Based  on  this  bioinformatics  study,  the  KSP  motifs
represent candidate  phosphorylation sites of MECP2.
Phosphorylation however, as the literature shows, has different effects on the two proteins.
While MECP2 becomes inactivated by phosphorylation and consequently dissociates from the
Bdnf promoter (Chen et al., 2003), phosphorylation of NEFH has been shown to slow down
filament transport in the axon (Ackerley et al., 2003).
Finally, a recent publication (Klose and Bird, 2004) suggests, that MECP2 has an elongated
shape which is supported by studies on its chicken homologue ARBP (von Kries et al., 1994).
This would correspond to the elongated form of NEFH.
4.2.2 MLLT2
There are currently no data on the structure of the MLLT2 protein AF-4 in the literature. Also
database searches did not result in any helpful hints. The only motif according to Pfam is the
AF-4  motif  (comprising  the  whole  AF-4  protein)  which  is  shared  by FMR2.  As  yet,  no
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function has been assigned to this AF-4 domain. 
Therefore  no  assumptions  on  the  shape  of  MECP2 can be  made with  the  help  of  AF-4.
However,  AF-4  has  been  reported  to  cause  ataxia  when mutated  (Isaacs  et  al.,  2003), a
symptom, that is also found in RTT.
4.3 MECP2 target genes
4.3.1 MECP2 regulates Fkbp5 expression
Our microarray study revealed genes potentially regulated by MECP2 in the mouse brain. The
expression  of  five  of  these  differentially  expressed  genes  was  known to  be  regulated  by
glucocorticoids. Based on these results, two major questions arose: A) Are these genes direct
targets of MECP2 or are the changes in gene expression due to secondary effects of loss of
MECP2 function  in the  brain?  B) How do glucocorticoids,  known to act  as  transcription
factors, interfere with transcription repression by MECP2? 
To address these questions, chromatin immunoprecipitation was established, which allowed to
analyze direct interactions of MECP2 with the genomic DNA of these potential targets. Fkbp5
was  chosen  to  be  studied  in  further  detail.  Three  MECP2 binding regions  were  revealed
(region 1,  region 2,  and GRE_2),  one  of which (GRE_2) can also be bound by the  GR.
Addition  of  the  glucocorticoid  dexamethasone  to  the  culture  medium of  primary neurons
induced binding of GR to  Fkbp5 while binding of MECP2 was abolished. In contrast,  the
glucocorticoid inhibitor RU-486 reverses the effect of dexamethasone and binding of MECP2
to the GRE_2 region is re-established.
A model  can therefore be proposed,  in  which GR and MECP2 control  the  expression of
Fkbp5 with glucocorticoids increasing and MECP2 decreasing the expression levels of Fkbp5.
GR and MECP2 compete for the binding to at least on locus in the Fkbp5 genomic region (i.e.
GRE_2).  If the concentration of either nuclear GR or MECP2 changes, the expression of
Fkbp5 will be altered (Fig. 28), which in turn leads to changes in GR signaling. This is due to
the fact, that FKBP5 itself is involved in GR signaling (Davies et al., 2002). FKBP5 is bound
to  the  GR  receptor  in  the  cytoplasm  and  replaced  by  FKBP4  after  binding  of  GR  to
glucocorticoids. This then leads to translocation of the receptor complex into the nucleus and
consequent gene expression regulation by GR.
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Fig.  28.  Model  of  Fkbp5 gene
regulation.  The GR and MECP2 regulate
the same gene. Stronger activation due to
higher  GR  levels  after  glucocorticoid
treatment or missing repression due to loss
of  function  of  MECP2,  both  situations  
lead to a stronger expression of the target 
gene (blue bar).
It is noteworthy, that MECP2 not only has one binding site in the Fkbp5 genomic region, but
seems to regulate Fkbp5 gene expression by binding to several loci. The first binding site is in
the proximal promoter, the second one near the start of the second exon. The third binding site
(GRE_2), however, is in the fifth intron, about 50 kb away from the core promoter. This raises
the  question  how  a  binding  far  downstream  of  the  transcription  start  can  influence  the
expression of the gene. Nevertheless, this regulatory element probably is important since at
least for the human FKBP5 gene it has been shown that expression is regulated by GR via a
binding site 2 kb downstream from the promoter (U et al., 2004). In addition, the results of
ChIPs with a GR antibody in this thesis prove that the GRE_2 region is a binding site for GR
in mouse.
An antibody specific for the C-terminal part of MECP2 was used to perform ChIP. Therefore,
binding of both MECP2 isoforms (MECP2e1 and MECP2e2) was detected simultaneously. In
follow-up studies  the  use  of  antibodies  specific  for  the  N-terminal  parts  of  MECP2e1 or
MECP2e2 should allow to determine if  the two variants bind to the same targets or have
different  specificities.  Antibodies  specific  for  an  N-terminal  antigen  might,  however,  be
difficult  to use in chromatin immunoprecipitation since the antigen would be close to the
MBD and therefore probably poorly accessible after binding to the DNA and formaldehyde
treatment.
4.3.2 Northern blot and quantitative real-time PCR results support the microarray
findings
Our collaborators in Edinburgh carried out experiments that substantiate our findings:
To confirm the results obtained by our microarray experiment, Northern blot analyses and
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quantitative real-time PCRs were carried out in Edinburgh. Their Northern blot results show
the differential  expression of these transcripts  in  wt as compared to symptomatic  Mecp2-/y
mice.
For  real-time  PCR  analysis,  Mecp2-null  mice  were  grouped  into  three  categories:  pre-
symptomatic,  early-symptomatic  and  late-symptomatic.  Male  Mecp2-null  mice  acquire
neurological symptoms at ~ 6 weeks of age and die at ~ 10 weeks. The postnatal onset of
symptoms resembles RTT, as the affected girls develop normal until the age of 6 – 18 months.
This raised the question whether the de-regulated expression of the Sgk and Fkbp5 genes seen
in late symptomatic mice was also present in animals that had yet to develop symptoms. As
there is considerable heterogeneity in the timing of symptom-onset and progression,  Mecp2-
null animals were classified according to symptoms rather than age using the criteria shown in
Table 28.
Phenotype Clasping Inertia Tremor Weight loss LOC* Average age
Presymptomatic - - - - - ~30d
Early symptomatic -/+ + + - - ~55d
Late symptomatic + + + + + ~ 70d
Table 28. Classification of Mecp2-null mice according to the manifestation of phenotype. The last column
shows the average age of mice displaying the symptoms. *LOC – loss of condition.
Real-time PCR, relative to Gapd as an internal control, revealed that Sgk and Fkbp5 are both
up-regulated in pre-symptomatic and early symptomatic mice in comparison to  wt controls
(Fig. 29B). Further analysis of the same cDNA samples established that many other genes
show indistinguishable expression levels in mutant and wt mice at all three stages (data not
shown) in agreement with previous results (Tudor et al., 2002). The de-regulation of Sgk and




                                                                                                                                                                                                                                                           
Fig.  29.  Northern  blot  and  real-time  PCR
results confirm microarray data.  A) Northern
blot analyzes of  Hsp105,  Cirbp,  Sgk and  Fkbp5
confirm the  microarray results  for  these  genes.
Total  brain  RNA  isolated  from  Mecp2-/y (ko),
heterozygote  Mecp2+/- (het)  and  wild-type  (wt)
control animals was used. Three litter mate pairs
(1, 2, 3) were investigated. The Mecp2-/y animals
showed  advanced  neurological  symptoms.
Intensities of the  Hsp105,  Cirp,  Sgk, and  Fkbp5
bands were normalized against a loading control
(S26 ribosomal protein cDNA probe). Expression levels of  wt animals were arbitrarily set to 1.0 and relative
expression levels of the respective ko and het litter mate samples are indicated below the lanes.  (B) Real time
PCR analyzes of Fkbp5 and Sgk in pre-symptomatic (pre) animals, and animals with early or late symptoms as
defined  in  Table  28.  Nine  wt and  nine  Mecp2-null  animals  were  investigated  per  stage.  A significant  up-
regulation of both genes was detected in all three investigated stages (see p-values). The mean is shown as a dot;
whiskers indicate ± the standard deviation. The y axes represent arbitrary threshold cycle number converted into
expression levels relative to Gapd expression.
4.3.3 Up-regulation of glucocorticoid–inducible Fkbp5 and Sgk in Mecp2-null animals is
not due to elevation of glucocorticoid levels 
As hyper-secretion of glucocorticoids has not been shown to induce expression of Fkbp5 and
Sgk in the brain, pumps were implanted into  wild-type mice  by Dr. Holmes in Edinburgh.
These pumps delivered a corticosterone solution at a constant rate. The effect on transcription
of  Fkbp5 and Sgk was measured. The experiments were performed by Northern analyses of
the mRNA levels in the brains of cortisol treated mice and vehicle treated control animals and
the results showed that two days of hormone exposure induced expression of both  Sgk and
Fkbp5 compared to animals that received the solvent vehicle alone (Fig. 30 A). To determine
whether the comparable level of induction of Sgk and Fkbp5 in Mecp2-null mouse brain is due
to high levels of circulating glucocorticoids, basal and stressed hormone levels were measured
in Edinburgh. There was no significant difference between the basal plasma glucocorticoid




                                                                                                                                                                                                                                                           
Fig. 30. Hormone-dependent and hormone-independent
induction  of  Fkbp5 and  Sgk in  mouse  brain.  (A)
Corticosterone  administration  induces  Fkbp5 and  Sgk
expression  in  wt  mouse  brain.   Hormone  (n  =  6)  or
hormone-free vehicle (n = 7) were delivered continuously
to wt mice for 2 days, after which Fkbp5 and  Sgk mRNA
levels in mouse brain were measured by Northern blotting.
Results  were  normalized  against  S26  ribosomal  protein
mRNA levels on the same blots. (B) Corticosterone levels
are not significantly elevated in Mecp2-null mice, although
Fkbp5 and Sgk are induced. Resting and stressed levels of
plasma  glucocorticoid  were  measured  in  symptomatic
Mecp2-null  mice  (ko)  and  wild-type litter  mates.
Experiment 1 (n = 4) and experiment 2 (n = 5) are shown
separately. Boxes depict mean plasma glucocorticoid values
and  whiskers  show  ± the  standard  deviation.  Statistical
analysis  using  Students  t-test  gave  p-values  for  the
comparison wt versus ko under basal conditions as 0.6673
(experiment 1 Exp1) and 0.5891 (Exp2). Under stressed conditions, p values were 0.141 (Exp1) and 0.1037
(Exp2). It can be concluded, that there are no significant differences between wt and ko hormone levels.
By ChIP analysis - carried out in Edinburgh - no changes in MECP2 binding to the regions
fkp and fkp1 could be shown after implantation of corticosterone pumps (see Fig. 31). This
suggests, that MECP2 and GR either regulate  Fkbp5 via independent sites or that there is
another binding site of MECP2 that can also be bound by GR (see Fig. 23, 24). As shown by
the experiments with glucocorticoid-treated primary neurons in this thesis, the GRE_2 region
probably is  such  a  binding  site.  This  region  has  not  been  studied  in  mice,  treated  with
corticosterone, so far.
Fig. 31. MECP2 binding to the Fkbp5 gene is not abolished in wt
mouse brain upon corticosterone infusion as shown by ChIP with
placebo and corticosterone-treated mice.  Rabbit serum is used a
negative control. mSin3A is a co-repressor complex interacting with
MECP2 and appears to  bind to the fkp1 site but not to the fkp region.
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The data presented in the Results section and the results obtained by our collaborators in
Edinburgh support the suggestion that certain downstream consequences of the glucocorticoid
pathway are constitutively activated in this mouse model, even though glucocorticoid levels
are not increased. Instead, the activation seems to be due to the missing repressor function of
MECP2. 
The activation of genes that are physiologically induced by glucocorticoids is in line with the
observation that mice with different mutations in the Mecp2 gene reportedly display seizures
and heightened anxiety that may be attributed to the inappropriate activation of stress response
genes (Chen et al., 2001; Shahbazian et al., 2002). 
4.3.4 Rett syndrome: a stress pathway disease - supporting evidence from the literature
Several pieces of evidence suggest that constitutive activation of glucocorticoid-responsive
genes may be relevant to our understanding of human RTT. Cortisol levels in Rett syndrome
patients appear normal (Echenne et al., 1991; Huppke et al., 2001), but the over-alertness and
agitation that  may result  from hormone-independent  activity of stress  pathways, including
prolonged fits of screaming and crying, are characteristic features of RTT. 
Elevated glucocorticoid exposure has profound, deleterious effects on the development of the
fetus and neonate, altering cell proliferation, migration, and differentiation (de Kloet  et al.,
1988).  Early  postnatal  administration  of  glucocorticoids  has  been  shown  to  result  in  an
adverse outcome at school age with some similarities to Rett  syndrome. Affected children
show  significantly  reduced  height  and  head  circumference,  poor  motor  skills  and  motor
coordination,  and significantly lower IQ scores (Yeh  et al.,  2004). Prenatal glucocorticoid
exposure  also  increases  anxiety  behavior  in  adult  offspring  (Welberg  et  al.,  2001)  and
postnatal exposure alters cerebellar development and function in rodents (Bohn et al., 1980).
The decreased dendritic branching and shortened dendrite arbors that have been described in
Rett syndrome patients (Armstrong, 2002) are also mimicked by chronic administration of
glucocorticoids,  leading  to  dendritic  atrophy  of  hippocampal  neurons  and  dendritic
reorganization  of  prefrontal  cortical  neurons  (Wellman,  2001).  In  addition,  osteopenia
frequently occurs  in  Rett  syndrome patients  and  is  a  known side-effect  of  glucocorticoid
exposure (Haas et al., 1997; Leonard et al., 1999; Budden and Gunness, 2001). 
In summary, many of the phenotypic features of Rett syndrome can be explained by altered
expression of the glucocortoid-regulated genes. Of course  Fkbp5  will not be the only gene
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regulated by MECP2 that contributes to the phenotype of the Rett  mouse model we used.
Rather the sum of many expression changes will constitute the disease. 
4.3.5 Repression by MECP2: global and total versus local and partial
The results of the Northern blot, RT-PCR, immunostainings, and ChIP experiments for Fkbp5
show,  that  MECP2  does  not  regulate  Fkbp5 in  an  "all-or-none"  manner,  but  is  rather
responsible for the fine tuning of Fkbp5 expression. Binding of MECP2 therefore might not
condense the chromatin completely, but result in a chromatin state that makes transcription
more difficult. Such an attenuating function of MECP2 has already been shown for the Bdnf
gene (Chen et al., 2003, Martinowich et al., 2003). 
If this model holds true for many other MECP2 targets, this would explain the difficulties
scientists  have had with microarray studies for Rett  syndrome. An attenuating function of
MECP2  would  lead  to  small  changes  in  gene  expression  which  are  hard  to  measure  by
microarray experiments. Tudor and colleagues could only detect subtle transcriptional changes
using different brain samples (Tudor et al., 2002) and the number of differentially expressed
genes found in this study is much lower than what would be expected for a transcription factor
with an extremely abundant binding site such as MECP2.
4.3.6 DNA microarray studies and chromatin immunoprecipitation
The  results  of  this  thesis  show,  that  the  combination  of  DNA  microarray  analysis  and
chromatin immunoprecipitation are extremely useful tools to find target genes of transcription
factors as well as the corresponding binding sites. The disadvantage is, that both techniques
are  not  trivial  require  laborious  optimization.  Some  critical  factors  for  chromatin
immunoprecipitation have been outlined in the results part.
This study also highlights, that the appropriate biological material has to be chosen to obtain
meaningful results. Only by using RNA from brain tissue of severely symptomatic  Mecp2-/y
mice for the microarray study and appropriate brain tissue as well as primary neurons for the
ChIP,  Fkbp5 could be detected as a direct target of MECP2. Microarray studies carried out
with  primary fibroblasts,  lymphoblastoid  cells  and  postmortem human  brain  did  not  find
Fkbp5 to  be  differentially  expressed.  The  binding  pattern  of  MECP2  in  fibroblasts  and
lymphoblastoid cells might be totally different from that in the brain. Even the more so if
MECP2 only has an attenuating function.
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In  that  perspective  it  would  be  interesting  to  hybridize  the  DNA  fragments  obtained  by
chromatin immunoprecipitation to a high-resolution genomic microarray covering the whole
genome. This would allow to identify many more, possibly all MECP2 targets in one single
experiment and enable a comparison of its binding pattern in different cell types and cellular
states possible.
4.3.7 Future studies
This study suggests that enhanced glucocorticoid signaling occurs in RTT patients and may be
therapeutically addressed by antagonists of the glucocorticoid pathway, e.g. at the GR level.
To  further  analyze the  interplay of  MECP2 and the  glucocorticoid  receptor  target  genes,
studies in animal models should be carried out in the future:
1.  Administration  of  glucocorticoid  pathway inhibitors  to  Rett  syndrome  animal  models
should reverse at least part of the phenotype.
2. If the activation of the glucocorticoid genes is due to loss of function of MECP2, a mouse
GR-null mutant crossed to the Mecp-/y strain should reverse the phenotype.
3. It will be interesting to see at what time point in development the regulation of Fkbp5 by
MECP2 starts. The answer should shed some light on the course of the disease and how long
it takes from the start of the dysregulation until the first symptoms appear.
4. Hybridization of the products of a ChIP with an anti-MECP2 antibody to a high-resolution
whole-genome microarray would allow to find additional genes and pathways involved in the
pathogenesis of Rett syndrome and might also resolve the questions why MECP2 mutations
have a brain-specific phenotype.
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4.4 Conclusions
Three aspects of MECP2, its function and its role in Rett syndrome have been studied in this
thesis.
• Six new MBD family proteins with possible functional redundancy to MECP2 were found.
Five of these proteins (SETDB1, SETDB2, BAZ2A, MBD5, and MBD6) are candidates to
compensate for the loss of function of MECP2 outside the brain in Rett patients.
• Database analysis  revealed homology of MECP2 to several  polypeptides  in  the human
proteome. The best matches were NF-H and MLLT2/AF4. A closer investigation of the
homologous regions indicated, that overall MECP2 might have an elongated structure and
revealed putative phosphorylation sites of MECP2.
• Finally, data presented in this thesis suggest, that downstream targets of the stress pathway
might be involved in the pathology of Rett syndrome. More specifically, MECP2 regulates
some genes that can be induced by glucocorticoids. Loss of function therefore leads to an
increase in expression of these genes, which  in turn may explain many features of the Rett
syndrome phenotype.  This  gives  rise  to  the  hope,  that  inhibitors  of  the  glucocorticoid
pathway could constitute a treatment for Rett syndrome patients.
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5. Zusammenfassung
Rett Syndrom, eine schwere Form der geistigen Behinderung, wird durch Mutationen in dem
X-chromosomalen  Gen  des  Methyl-CpG  bindenden  Proteins  2  (MECP2)  verursacht  und
kommt fast ausschließlich bei Mädchen vor. Mutationen in  MECP2 wurden erstmals 1999
beschrieben,  die  molekularen  Mechanismen,  welche  der  Krankheit  zugrunde  liegen,  sind
bisher  aber  unbekannt.  Eine  bekannte  Funktion  von  MECP2  ist  die  der  Transkription-
Repression. 
Lediglich  zwei  neuronale  Zielgene  (Bdnf und  Dlx5)  wurden  jedoch  bisher  beschrieben.
Obwohl  MECP2 ubiquitär  exprimiert  ist,  besteht  bei  Rett  Syndrom Patienten  ein  primär
neuronaler Phänotyp. Diese Beobachtung lässt die Vermutung zu,  dass MECP2 im Gehirn
eine  wichtige  Funktion  erfüllt,  während in  peripheren Geweben  der  Funktionsverlust  von
MECP2 durch ein funktionell redundantes Protein kompensiert werden könnte.
Um Proteine  zu finden,  die  eine solche  kompensatorische Funktion übernehmen könnten,
wurden zwei Strategien angewandt. Im ersten Projekt wurde mit bioinformatischen Mitteln
nach Proteinen gesucht, die ebenso wie MECP2 eine methyl-CpG bindende Domäne (MBD)
besitzen.  Sechs  solcher  Proteine  wurden  gefunden  und  auf  ihre  Expression  und
Domänenstruktur hin untersucht.
Das zweite Projekt zielte darauf ab, Proteine zu identifizieren, die eine globale Ähnlichkeit zu
MECP2 aufweisen. Solche Proteine sollten Rückschlüsse auf die Form und eventuell sogar
auf bisher unbekannte Funktionen von MECP2 zulassen. Zwei solche paralogen Polypeptide
wurden gefunden und die Struktur  eines dieser,  NEFH, lässt  vermuten, dass MECP2 eine
längliche Form hat. Der Sequenzvergleich zwischen NEFH und MECP2 deutet zudem auf
eine potentielle Phosphorylierungsstelle in MECP2 hin.
Um Zielgene  von MECP2 im Gehirn zu  finden,  wurde  die  Chromatinimmunpräzipitation
(ChIP)  etabliert  und  mit  cDNS-Mikroarray  Untersuchungen  eines  Mausmodells  für  Rett
Syndrom kombiniert.  Die Auswertung der Mikroarray-Daten  zeigte,  dass in  diesen Tieren
mehrere  Gene  differenziell  exprimiert  sind,  die  normalerweise  während  der  Stressanwort
durch  Glukokortikoide  reguliert  werden.  Erhöhte  mRNS-Werte  konnten  für  die  "Plasma
Glukokortikoid-induzierbare  Kinase  1"  (Sgk)  sowie  für  das  "FK506-bindende Protein  51"
(Fkbp5) nachgewiesen werden. Durch Immunfärbung histologischer Gehirnschnitte, konnte
gezeigt  werden,  dass  Mecp2 und  Fkbp5 sowie  Sgk in  denselben  Zellen  des  Gehirns
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synthetisiert  werden.  Dies  legt  nahe,  dass  MECP2  eher  eine  Modulation  der  Expression
bewirkt, als eine komplette Repression.
Mittels  ChIP konnten  drei  Bindungsstellen  von  MECP2  in  der  genomischen Region  von
Fkbp5 gefunden werden. Eine dieser Bindungsstellen kann zudem auch vom Glukokortikoid-
Rezeptor  (GR)  gebunden  werden.  Aufgrund  dieser  Ergebnisse  wurde  eine  Hypothese
formuliert,  nach  der  MECP2  und  GR  um  die  Bindung  an  eine  Region  im  Fkbp5 Gen
konkurrieren und beide die Expression von FKBP5 regulieren. In Rett Syndrom Patienten ist
diese Regulation auf Grund des Funktionsverlusts von MECP2 gestört. Dies würde zu einer
Überexpression von Glukokortikoid-regulierten Genen führen, wodurch mehrere Merkmale
des Rett Syndrom-Phänotyps erklärt werden könnten.
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6. Annex
6.1 Sequence alignment of MECP2 and NEFH
MECP2        ------------------------------------------------------------
NEFH         MMSFGGADALLGAPFAPLHGGGSLHYALARKGGAGGTRSAAGSSSGFHSWTRTSVSSVSA
                                                                            
MECP2        ------------------------------------------------------------
NEFH         SPSRFRGAGAASSTDSLDTLSNGPEGCMVAVATSRSEKEQLQALNDRFAGYIDKVRQLEA
                                                                            
MECP2        ------------------------------------------------------------
NEFH         HNRSLEGEAAALRQQQAGRSAMGELYEREVREMRGAVLRLGAARGQLRLEQEHLLEDIAH
                                                                         
MECP2        ------------------------------------------------------------
NEFH         VRQRLDDEARQREEAEAAARALARFAQEAEAARVDLQKKAQALQEECGYLRRHHQEEVGE
                                                                         
MECP2        ------------------------------------------------------------
NEFH         LLGQIQGSGAAQAQMQAETRDALKCDVTSALREIRAQLEGHAVQSTLQSEEWFRVRLDRL
                                                                         
MECP2        ------MVAGMLGLREEKSEDQDLQGLKDKPLKFKKVKKD--------------------
NEFH         SEAAKVNTDAMRSAQEEITEYRRQLQARTTELEALKSTKDSLERQRSELEDRHQADIASY
                    . .* . :** :* :     : . *:  * .**                    
MECP2        ------------------------------------------------------------
NEFH         QEAIQQLDAELRNTKWEMAAQLREYQDLLNVKMALDIEIAAYRKLLEGEECRIGFGPIPF
                                                                         
MECP2        ---------------------------------------------------KKEEKEGKH
NEFH         SLPEGLPKIPSVSTHIKVKSEEKIKVVEKSEKETVIVEEQTEETQVTEEVTEEEEKEAKE
                                                                ::****.*.
MECP2        EPVQPSAHHSAEPAEAGKAETSEGSGSAPAVPEASAS---PKQRRSIIRDRGPMYDDPTL
NEFH         EEGKEEEGGEEEEAEGGEEETKSPPAEEAASPEKEAKSPVKEEAKSPAEAKSPEKEEAKS
             *  : .   . * **.*: **.. ... .* ** .*.    :: :*  . :.*  ::.. 
MECP2        PEGWTRKLKQRKSGRSAGKYDVYLINPQGKAFRSKVELIAYFEKVGDTSLDPNDFDFTVT
NEFH         PAEVKSPEKAKSPAKEEAKSPPEAKSPEKEEAKSPAEVKSPEKAKSPAKEEAKSPAEAKS
             *   .   * :...:. .*      .*: :  :* .*: :  :  . :. :.:.   : :
MECP2        GR------------------------------------GSPSRREQKPPKKPKSPKAP--
NEFH         PEKAKSPVKEEAKSPAEAKSPVKEEAKSPAEVKSPEKAKSPTKEEAKSPEKAKSPEKEEA
              .                                     **::.* *.*:*.***:    
MECP2        GTGRGRGRPKGSGTTRPKAATSEGVQVKRVLE--KSPGKLLVKMP-FQTSPGGKAEGGGA
NEFH         KSPEKAKSPVKAEAKSPEKAKSPVKAEAKSPEKAKSPVKEEAKSPEKAKSPVKEEAKSPE
              : .    *  : :. *: *.*      :  *  *** *  .* *   .**  :   .  
MECP2        TTSTQVMVIKRPGRKRKAEADPQAIPKKRGRKPGSVVAAAAAEAKKKAVKESSIRSVQET
NEFH         KAKSPVKEEAKTPEKAKSPVKEEAKSPEKAKSPEKAKTLDVKSPEAKTPAKEEARSPADK
             .:.: *    :. .* *: .. :* . ::.:.* .. :  . ..: *:  :.. **  :.
MECP2        VLPIKKRKTRETVSIEVKEVVKPLLVSTLGEKSGKGLKTCKSPGR--------KSKESSP
NEFH         FPEKAKSPVKEEVKSPEKAKSPLKEDAKAPEKEIPKKEEVKSPVKEEEKPQEVKVKEPPK
             .    *  .:* *.   *        :.  **.    :  *** :        * **.. 
MECP2        KGRSSSASSPPKKEHHHHHHHSESPKAPVP---LLPPLPPPPPEPESSEDPTSPPEPQDL
NEFH         KAEEEKAPATPKTEEKKDSKKEEAPKKEAPKPKVEEKKEPAVEKPKESKVEAKKEEAEDK
             *.....*.:.**.*.::. ::.*:**  .*   :     *.  :*:.*:  :.  *.:* 
MECP2        SSSVCKEEKMPRGGSLESDGCPKEPAKTQPAVATAATAAEKYKHRGEG----ERKDIVSS
NEFH         KKVPTPEKEAPAKVEVKEDAKPKEKTEVAKKEPDDAKAKEPSKPAEKKEAAPEKKDTKEE
             ..    *:: *   .::.*. *** ::.    .  *.* *  *   :     *:**  ..
MECP2        SMPRPNRE----------------EPVDSRTPVTERVS----------------------
NEFH         KAKKPEEKPKTEAKAKEDDKTLSKEPSKPKAEKAEKSSSTDQKDSKPPEKATEDKAAKGK
             .  :*:.:                ** ..::  :*: *
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